Annals of the Rheumatic Diseases

A journal of clinical rheumatology and connective tissue research

Editor J. T. Scott

Associate Editors H. L. F. Currey V. Wright

Editorial Committee
B. M. Ansell John Ball C. G. Barnes W. W. Buchanan
E. G. L. Bywaters A. St. J. Dixon D. C. Dumonde R. B. Duthie
D. L. Gardner L. E. Glynn E. B. D. Hamilton E. J. Holborow
V. H. T. James A. G. Mowat Helen Muir B. Vernon-Roberts
K. W. Walton P. H. N. Wood
Editor *British Medical Journal*

Appointed by the British Medical Association and the Arthritis and Rheumatism Council for Research

Technical Editor
Susan Burkhart

VOLUME 34, 1975

LONDON
BRITISH MEDICAL ASSOCIATION
TAVISTOCK SQUARE WC1H 9JR

CONTENTS OF VOLUME 34

No. 1. FEBRUARY, 1975

Rheumatoid synovitis and joint disease. Relationship between arthroscopic and histological changes
D. B. Yates and J. T. Scott 1

Lack of correlation of synovial histology with joint damage in rheumatoid arthritis
D. R. F. Henderson, M. I. V. Jayson, and C. R. Tribe 7

Development of periarticular osteophytes in experimentally induced osteo-arthritis in the dog. A study using microradiographic, microangiographic, and fluorescent bone-labelling techniques
E. M. M. Gilbertson 12

Development with age of human articular cartilage surface structure. A survey by interference microscopy of the lateral femoral condyle
R. B. Longmore and D. L. Gardner 26

Macrophage-lymphocyte clustering in rheumatoid arthritis
F. W. S. Webb, M. Baker, R. Weisbart, R. Bluestone, and L. Goldberg 38

Virus antibodies in serum and synovial fluid of patients with rheumatoid arthritis and other connective tissue diseases
J. L. Kalliomäki, P. Halonen, and A. Salmi 43

Influence of tubercle aggregate size on severity of adjuvant arthritis in the rat
S. P. Liyanage, H. L. F. Currey, and B. Vernon-Roberts 49

Observations on phagocytosis of urate crystals by polymorphonuclear leucocytes
K. T. Rajan 54

Acute knee joint rupture after yttrium 90 injection
P. Davis and M. I. V. Jayson 62

Histological study of effects of colloidal 90 yttrium on knee joint tissues of rabbits
K. Pavelka, W. Meier-Ruge, W. Müller, and R. Fridrich 64

Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction
J. Webb, K. Whaley, R. N. M. MacSween, G. Nuki, W. Carson Dick, and W. Watson Buchanan 70

Terminal phalangeal osteosclerosis
W. Halim, J. K. van der Korst, H. A. Valkenburg, and Ph. van Elteren 82

Temporo-mandibular joint disease in ankylosing spondylitis
C. Davidson, J. A. Wojtulewski, P. A. Bacon, and D. Winstock 87

Pre-ankylosing spondylitis. Histopathological report
E. G. Pasion and J. W. Goodfellow 92

Rheumatoid plantar synovial cysts
H. Bienenstock 98

Occasional Survey. Bone and ageing
J. Dequeker 100

Book reviews 116

Note 116

No. 2. APRIL, 1975

MIF production of lymphocytes from patients with rheumatoid arthritis with antigen–antibody complexes
M. M. Eibl and C. Sitko 117

Lymphocyte proliferation to artery antigen as a positive diagnostic test in polymyalgia rheumatica
B. L. Hazleman, I. C. M. MacLennan, and M. M. Esiri 122

Rheumatoid arthritis in an urban South African Negro population
L. Solomon, G. Robin, and H. A. Valkenburg 128

Rheumatoid arthritis in a rural South African Negro population
P. Beighton, L. Solomon, and H. A. Valkenburg 136

Antiglobulins in Nigerians with rheumatoid disease
G. O. Okafor, M. W. Turner, and B. M. Greenwood 142

Immunoglobulin phagocytosis by granulocytes from sera and synovial fluids in various rheumatoid and nonrheumatoid diseases
A. Cats, G. J. M. Lafeber, and F. Klein 146

Granulopoietic activity in Felty's syndrome
R. Gupta, W. A. Robinson, and D. Albrecht 156

Significance of plasma copper and caeruloplasmin concentrations in rheumatoid arthritis
D. P. Bajpayee 162

Behaviour of synovial complement C3 and C4 components in inflammatory and degenerative joint diseases, before and after synoviorthesis
R. Gabay, A. Micheli, and G. H. Fallet 166

Chronic monarticular synovitis. Diagnostic and prognostic features
M. R. Fletcher and J. T. Scott 171

Survey of joint mobility and *in vivo* skin elasticity in London schoolchildren
S. Silverman, L. Constine, W. Harvey, and R. Grahame 177

Empyema in rheumatoid arthritis
P. A. Dieppe 181

A double blind trial to assess the value of alclofenac compared with phenylbutazone in the management of rheumatoid arthritis
M. A. Chamberlain and V. Wright 186

Feprazone, a new anti-inflammatory agent. Studies of potency and gastro-intestinal tolerance
M. R. Fletcher, W. Loebl, and J. T. Scott 190

Supplements to *Annals of the Rheumatic Diseases* 194

Heberden Society (Bristol) 195

Heberden Society (Manchester) 200

Notes 204

No. 3. JUNE, 1975

DNA polymerase activity in rheumatoid synovial membranes
M. Norval, M. M. Ogilvie, and B. P. Marmion 205

Naturally occurring anti-inflammatory factors in the synovial fluids of patients with rheumatic disease and their possible mode of action
R. B. Capstick, D. A. Lewis, and J. A. Cosh 213

Proliferation of synovial lining cells and fibroblasts
W. Mohr, G. Beneke, and W. Mohing 219

Proteinase inhibitors in rheumatoid arthritis
D. Brackertz, J. Hagmann, and F. Kueppers 225

Lymphocyte reactivity in rheumatoid arthritis. Mixed lymphocyte culture
E. M. Caperton, Jr., D. R. Baker, and R. A. King 231

Relationships between rheumatoid cells in culture
D. G. Palmer 235

Double-stranded RNA antibodies in systemic lupus erythematosus
P. Davis, P. Cunnington, and G. R. V. Hughes 239

Raised serum creatine phosphokinase activity in ankylosing spondylitis
A. Calin 244

Clinical and biochemical observations on three cases of hypoxanthine-guanine phosphoribosyltransferase deficiency
D. N. Bunn, I. K. Moss, A. Nicholls, J. T. Scott, M. L. Snaith, and M. R. Watson 249

Single daily dose of allopurinol
I. Brewis, R. M. Ellis, and J. T. Scott 256

Familial chondrocalcinosis in the Chiloe Islands, Chile
A. J. Reginato, J. L. Hollander, V. Martinez, F. Valenzuela, V. Schiapachasse, E. Covarrubias, S. Jacobelli, R. Arinoviche, D. Silcox, and F. Ruiz 260

Pigmented villonodular synovitis in multiple joints. Occurrence in a child with cavernous haemangioma of lip and pulmonary stenosis
J. Leszczynski, J. R. Huckell, J. S. Percy, J. C. LeRiche, and B. C. Lentle 269

Report of Symposium: Penicillamine 273

Correspondence 275

Book review 276

Note 276

No. 4. AUGUST, 1975

Some new evidence on human joint lubrication
A. Unsworth, D. Dowson, and V. Wright 277

Quantitative study of stiffness in the knee joint
C. H. Such, A. Unsworth, V. Wright, and D. Dowson 286

The foot in chronic rheumatoid arthritis
E. Vidigal, R. K. Jacoby, A. St. J. Dixon, A. H. Ratliff, and J. Kirkup 292

Attempt to classify patients with arthritis of the hip suitable for prosthetic replacement, and their femoral heads
P. D. Byers, B. A. Roper, and B. Glennie 298

Breakdown of proteoglycan and collagen induced in pig articular cartilage in organ culture
J. T. Dingle, P. Horsfield, H. B. Fell, and M. E. J. Barratt 303

Aortic valve incompetence and replacement in rheumatoid arthritis
J. M. I. Iveson, U. Thadani, M. Ionescu, and V. Wright 312

Cardiac valvular disease in chronic inflammatory disorders of connective tissue. Factors influencing survival after surgery
D. B. Yates and J. T. Scott 321

Assessment of anti-inflammatory drugs in the rat using subcutaneous implants of polyurethane foam impregnated with dead tubercle bacilli
A. K. Clarke, B. Vernon-Roberts, and H. L. F. Currey 326

Nucleation of monosodium urate crystals
W. R. Wilcox and A. A. Khalaf 332

Urinary copper excretion in rheumatoid arthritis
W. McMurray, W. M. Martin, P. Scudder, J. Stocks, A. G. White, and T. L. Dormandy 340

Protein sulphydryl depression during adjuvant arthritis
A. Lorber, J. Leeb, P. Carroll, Jr., W. Baumgartner, and V. Hill 346

Eosinophil-specific and other granulocyte-specific antinuclear antibodies in juvenile chronic polyarthritis and adult rheumatoid arthritis
J. N. Rosenburg, G. D. Johnson, E. J. Holborow, and E. G. L. Bywaters 350

Rubella antibody levels in juvenile rheumatoid arthritis
C. C. Linnemann, Jr., J. E. Levinson, C. R. Buncher, and G. M. Schiff 354

Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers. Rotorua Lakes study 3
J. M. Stanhope and I. A. M. Prior 359

Reiter's disease in three boys
J. M. I. Iveson, B. S. Nanda, J. A. H. Hancock, P. J. Pownall, and V. Wright 364

Failure to show mycoplasmas and cytopathogenic virus in rheumatoid arthritis
P. J. Middleton and T. C. Highton 369

Antinative DNA antibodies as a reaction to pyrazole drugs
M. F. Grayson, V. M. Martin, and R. L. Markham 373

Symmetrical joint involvement
E. G. L. Bywaters 376

Book reviews 377

Notes 378

No. 5. OCTOBER, 1975

New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population
R. M. Acheson and A. B. Collart 379

Wrist cysts and fistulae. An arthrographic study of the rheumatoid wrist
J. M. I. Iveson, A. G. S. Hill, and V. Wright 388

Laboratory diagnosis of rheumatoid arthritis. Prospective study of 85 patients
C. E. Bayliss, R. L. Dawkins, G. Cullity, R. E. Davis, and J. B. Houliston 395

Rheumatoid arthritis of the elbow. Pattern of joint involvement, and results of synovectomy with excision of the radial head
H. Stein, R. A. Dickson, and G. Bentley 403

Phenylbutazone and chromosomal damage
S. Walker, D. A. Price Evans, P. A. Benn, T. R. Littler, and L. D. C. Halliday 409

Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen
A. St. J. Dixon, J. Davies, T. L. Dormandy, E. B. D. Hamilton, P. J. L. Holt, R. M. Mason, M. Thompson, J. C. P. Weber, and D. W. Zutshi 416

Hyperbasophilic immunoblasts in circulating blood in chronic inflammatory rheumatic and collagen diseases
F. Delbarre, A. Le Gô, and A. Kahan 422

Persistence of antigen in nonarthritic joints
A. Fox and L. E. Glynn 431

Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus
J. Holian, I. D. Griffiths, D. N. Glass, R. N. Maini, and J. T. Scott 438

Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis
M. K. Adler, A. Baumgarten, B. Hecht, and N. J. Siegel 444

Hypertension in relation to musculoskeletal disorders
J. S. Lawrence 451

Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies
P. B. Yeo and R. Sinniah 457

Heberden Society 461

Book reviews 470

No. 6. DECEMBER, 1975

Heberden Oration, 1974. Human arthritis applied to animal models. Towards a better therapy
D. A. Willoughby 471

Xeroradiographic techniques applied to assessment of Achilles tendon in inflammatory or metabolic diseases
J. C. Gerster, H. Hauser, and G. H. Fallet 479

Fistulization of rheumatoid joints. Spectrum of identifiable syndromes
R. F. Shapiro, D. Resnick, J. J. Castles, R. D'Ambrosia, P. R. Lipscomb, and G. Niwayama 489

Ectopic calcification around joints of paralysed limbs in hemiplegia, diffuse brain damage, and other neurological diseases
A. J. Rosin 499

Potassium metabolism in patients with rheumatoid arthritis. Effects of treatment with depot tetracosactrin, spironolactone, and oral supplements of potassium chloride
G. Nuki, K. Boddy, A. C. Kennedy, P. King, A. M. Duncan, and W. W. Buchanan 506

Cartilage of the patella. Topographical variation of glycosaminoglycan content in normal and fibrillated tissue
C. Ficat and A. Maroudas 515

Activation of human leucocyte procollagenase by rheumatoid synovial tissue culture medium
J. Wize, T. Abgarowicz, E. Wojtecka-Lukasik, S. Ksiezny, and A. M. Dancewicz 520

Study of lymphoid cells from inflamed synovial membranes
G. Loewi, E. M. Lance, and J. Reynolds 524

Effect of intra-articular injection of radioactive colloids of erbium and yttrium on the growth of rabbit legs
C. Rebut-Bonneton, J. C. Roucayrol, and F. Delbarre 529

Myelomonocytic leukemia following cyclophosphamide therapy of rheumatoid disease
R. R. Love and J. M. Sowa 534

Neurofibrosarcoma following radiotherapy for ankylosing spondylitis
S. J. Bentley, P. Davis, and M. I. V. Jayson 536

Obituary 539

Heberden Society 540

Notes 544

Book reviews 546

Index 550

Ann. rheum. Dis. (1975), **34**, 550

INDEX TO VOLUME 34, 1975

P. = Proceedings of the Heberden Society
S1 = Supplement 1
S2 = Supplement 2

The Supplements were published separately in February 1975 and December 1975.

ABGAROWICZ, T., *see* WIZE, J. *et al.*
ACHESON, R. M., and COLLART, A. B.: New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population, 379
Achilles tendon, in inflammatory or metabolic diseases, xeroradiographic techniques applied to, 479
ADAMS, P., and MUIR, H.: Biochemical studies of individual lumbar discs, 467, *P.* 495
Adjuvant arthritis, influence of tubercle aggregate size on severity, rat, 49
ADLER, M. K., BAUMGARTEN, A., HECHT, B., and SIEGEL, N. J.: Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis, 444
Ageing and bone: occasional survey, 100
AHO, K., AHVONEN, P., ALKIO, P., LASSUS, A., SAIRANEN, E., SIEVERS, K , and TIILIKAINEN, A.: HL-A 27 in reactive arthritis following infection, *S1*/29
AHVONEN, P., *see* AHO, K. *et al.*
AKESON, W. H., WOO, S. L.-Y., AMIEL, D., MATTHEWS, J. V. and RUTHERFORD, L.: Lubrication defect of immobilized connective tissue matrices, *S2*/101
ALBRECHT, D., *see* GUPTA, R. *et al.*
Alcian blue, staining in articular cartilage, *S2*/17
Alclofenac, compared with phenylbutazone, double blind trial in rheumatoid arthritis, 186
ALI, S. Y., and BAYLISS, M. Y.: Enzymes involved in degradation of cartilage in osteoarthrosis, *S2*/65
—— and WISBY, A.: Ultrastructural aspects of normal and osteoarthrotic cartilage, *S2*/21
ALKIO, P., *see* AHO, K. *et al.*
ALLISON, A.: Concluding remarks, histocompatibility and disease, *S1*/59
Allopurinol, single daily dose, 256, 201, *P.*
AMIEL, D., *see* AKESON, W. H. *et al.*
ANDERSON, J., *see* KENNEDY, A. C. *et al.*
Ankylosing spondylitis, cardiac lesions, 195, *P.*
—— —— family studies, *S1*/39
—— —— frequency of atypical gene E_1^a of serum cholinesterase, 198, *P.*
—— —— and HL-A 27, *S1*/1
—— —— —— antigens, *S1*/42
—— —— —— family study, *S1*/53
—— —— lymphocyte function in, *S1*/49
—— —— neurofibrosarcoma following radiotherapy, 536
—— —— pre-ankylosing stage, histopathological report, 92
—— —— raised levels of complement inactivation products in , 202, *P.*
—— —— raised serum creatine phosphokinase, 244
—— —— temporo-mandibular joint disease, 87, 468, *P.*
ANSELL, B., SIDLER, J., and ZINN, W. M.: Radiological changes in the age group 5 to 24 years of the population of Azmoos, Switzerland, 199, *P.*
—— *see also* HALL, M. A. *et al.*
HOWARD, A. *et al.*
ANSTUTZ, H. C., *see* CLARKE, I. C. *et al.*
Antibodies(y), antinuclear, DNA binding capacity and electroprecipitation, serum complement level, presence of soluble complexes, relationship in systemic lupus erythematosus and rheumatoid arthritis, 469, *P.*
—— —— eosinophil-specific and granulocyte-specific, in juvenile chronic polyarthritis and adult rheumatoid arthritis, 350, 468, *P.*
—— —— DNA human, reference standards for diagnosis and management of systematic lupus erythematosus, 438
—— —— —— *see also* DNA
——-mediated leucocyte cytotoxicity to Chang human liver cells in rheumatoid arthritis and other diseases, 544, *P.*
—— rubella, in juvenile rheumatoid arthritis, 354
—— streptococcal, joint morbidity, and uric acid, in Maori and European teenagers, Rotorua lakes study 3, 359
Antigens, mixed lymphocyte reaction stimulating, *S1*/7
—— persistence in nonarthritic joints, 431
—— *see also* HL-A
Antiglobulins in rheumatoid disease, Nigerians, 142
Anti-inflammatory drugs, *see* Drugs
Antinuclear factor, immunofluorescence method for differentiation between RA and healthy persons, and SLE and scleroderma, 197, *P.*
Aortic valve incompetence and replacement in rheumatoid arthritis, 312, 464, *P.*
ARINOVICHE, R., *see* REGINATO, A. J. *et al.*
ARLOT, M., *see* VIGNON, E. *et al.*
ARTMANN, G., *see* FEHR, K. *et al.*
Arthritides, sero-negative, impaired cell mediated immunity, 203, *P.*
Arthritis, adjuvant, protein sulphydryl depression during, 346
—— of hip, classification of patients suitable for prosthetic replacement, and their femoral heads, 298
—— human applied to animal models, towards a better therapy: Heberden Oration, 1974, 471
—— reactive, following infection, HL-A 27 in, *S1*/29
—— rheumatoid, *see* Rheumatoid arthritis

Articular cartilage, calcium and phosphate ions, equilibria, *S2*/46
—— —— cerebroside sulphatides synthesis, *S2*/62
—— —— chick xyphoid, procollagen, *S2*/40
—— —— collagen-glycosaminoglycan interaction, passive agglutination method, *S2*/38
—— —— collagen, nature and location of crosslinks, *S2*/41
—— —— degeneration, initial stage, *S2*/125
—— —— degraded, reversible transformation of chondrocytes, *S2*/146
—— —— elastic modulus, determination, *S2*/116
—— —— in experimental osteoarthrosis, ultrastructure and histology, *S2*/136
—— —— fatigue testing, *S2*/108
—— —— fibrillation versus ink-staining patterns, *S2*/12
—— —— fluid transport, *S2*/77, *S2*/82
—— —— glycosaminoglycans, *see* Glycosaminoglycans
—— —— growth hormone action on, in organ culture, *S2*/74
—— —— histogenesis, *S2*/19
—— —— knee joint, glycosaminoglycan variation with surface site, *S2*/44
—— —— injury threshold, experimental evidence, *S2*/140
—— —— interaction of cartilage fibrils and proteoglycans, *S2*/32
—— —— lesions, Liverpool population, *S2*/122
—— —— load bearing function, knee joint menisci, *S2*/118
—— —— lysozyme function, *S2*/69
—— —— matrix, structure, *S2*/20
—— —— —— three-dimensional observations, *S2*/21
—— —— mechanical behaviour, *S2*/104
—— —— mechanical model, *S2*/115
—— —— mechanical properties, relationship to matrix degradation and age, *S2*/111
—— —— membrane bones, avian, differentiation and maintenance, *S2*/145
—— —— metabolic turnover, *S2*/55
—— —— osteoarthrosis, enzymes in degradation, *S2*/65
—— —— —— femoral head, histological changes, *S2*/134
—— —— —— human, and normal bovine, chain composition of pepsin-solubilized collagen, *S2*/35
—— —— —— and normal, ultrastructural aspects, *S2*/21
—— —— —— SEM, *S2*/23
—— —— patella, and its degeneration, *S2*/135
—— —— proteoglycan aggregates, structure and stability, *S2*/26, *S2*/29
—— —— proteoglycans, biosynthesis, *S2*/52
—— —— —— breakdown and collagen in organ culture, pig, 303
—— —— —— charged group behaviour in relation to pH, *S2*/44
—— —— —— discontinuous nature of protein-keratan core, *S2*/42
—— —— scanning electron microscopy, human, *S2*/5
—— —— sequential changes, superficial defects, SEM, *S2*/8
—— —— stain distribution with alcian blue, *S2*/17
—— —— surfaces, lubricating monolayers, *S2*/100
—— —— —— microscopical appearances and organization, *S2*/2
—— —— —— structure, development, 26
—— —— symposium, London, September 2–6, 1974, announcement, 204, 545
—— —— vascularization, *S2*/76
—— —— wear properties, *S2*/117

Bacon, P. A., Cracchiolo, A., Bluestone, R., and Goldberg, L. S.: Cell mediated immunity to synovial antigens in rheumatoid arthritis, 196, *P.*
—— *see also* Davidson, C. *et al.*
Badley, E. M., Ball, J., and Wood, P. H. N.: Interpreting the biological significance of rheumatoid factor, 463, *P.*
Bailey, A., *see* Scott, J. E. *et al.*
Bailey, A. J., *see* Herbert, C. M. *et al.*
—— *see also* Balian, G., and Bailey, A. J.
Bajpayee, D. P.: Significance of plasma copper and caeruloplasmin concentrations in rheumatoid arthritis, 162
Baker, D. R., *see* Caperton, E. M. *et al.*
Baker, M., *see* Webb, F. W. S. *et al.*
Balian, G., and Bailey, A. J.: Nature and location of crosslinks in cartilage collagen, *S2*/41
Ball, J., *see* Badley, E. M. *et al.*
Hilton, R. C. and Ball, J.
Barratt, M. E. J., *see also* Dingle, J. T. *et al.*
Poole, A. R. *et al.*
Barret, A. J., *see* Sturrock, R. D. *et al.*
Barritt, D. W., *see* Cosh, J. A. *et al.*
Batchelor, J. R.: Identification of HL-A antigens by serological criteria, *S1*/4
Baumgarten, A., *see* Adler, M. K. *et al.*
Baumgartner, W., *see* Lorber, A. *et al.*
Bayliss, C. E., Dawkins, R. L., Cullity, G., Davis, R. E. and Houliston, J. B.: Laboratory diagnosis of rheumatoid arthritis. Prospective study of 85 patients, 395
Bayliss, M. T., *see* Ali, S.Y., and Bayliss, M. T.
Begernholtz, A., *see* Smith, T. W. D. *et al.*
Behçet's disease, family study, *S1*/53
Beighton, P., Solomon, L., and Valkenburg, H. A.: Rheumatoid arthritis in a rural South African Negro population, 136
—— *see also* Solomon, L. *et al.*
Bell, M. A., *see* Brooks, P. M. *et al.*
Benderly, H., and Maroudas, A.: Equilibria of calcium and phosphate ions in human articular cartilage, *S2*/46
Beneke, G., *see* Mohr, W. *et al.*
Benn, P. A., *see* Walker, S. *et al.*
Benn, T., and Wood, P. H. N.: Generalized osteoarthritis. A problem of definition, 466, *P.*
Bentley, S. J., Davis, P., and Jayson, M. I. V.: Neurofibrosarcoma following radiotherapy for ankylosing spondylitis, 536
Bienenstock, H.: Rheumatoid plantar synovial cysts: case report, 98
Bitter, T., *see* De Bosset, Ph., and Bitter, T.
Bjelle, A.: Variations in glycosaminoglycans with surface site in human knee joint cartilage, *S2*/44
Bluestone, R., Goldberg, L. S., Weisbart, R. H., Morris, R. I., and Holborow, E. J.: Aberrant immunity in (HL-A) W27-positive rheumatic disease, *S1*/46
—— Morris, R. I., Metzger, A. L., and Terasaki, P. I.: (HL-A) W27 and the spondylitis of chronic inflammatory bowel disease and psoriasis, *S1*/31

—— *see also* BACON, P. A. *et al.*
WEBB, F. W. S. *et al.*
BODDY, K., *see* NUKI, G. *et al.*
BODMER, W. F.: The HL-A system and its association with immune responses and disease, *S1*/13
Bone and ageing: occasional survey, 100
—— density in osteoarthrosis, *S2*/130
BONI, A., *see* FEHR, K. *et al.*
RAU, R. *et al.*
BONNETON, C. REBUT-, *see* REBUT-BONNETON, C.
BOOK REVIEWS
ALI, S. Y., ELVES, M. W., and LEABACK, D. H., *editors*: Normal and osteoarthrotic articular cartilage, Institute of Orthopaedics symposium, November 1973, 1974. 470
Clinics in rheumatic diseases. Vol. I, No. 1, April 1975, 548.
COHEN, A. S., *editor*: Laboratory diagnostic procedures in the rheumatic diseases, 2nd ed., 1975, 547.
DE SEZE, S., RYCKEWAERT, A., KAHN, M.-F., and VITALE, C.: L'Actualite Rhumatologique 1974. Breviare de rhumatologie, 4th ed. 1975, 546.
DUBOIS, E. L., *editor*: Lupus erythematosus, 2nd ed., 1974. 377.
FESSEL, W. J.: Rheumatology for clinicians, n.d., 547.
FRICKE, R., and HARTMANN, F., *editors*: Connective tissues: biochemistry and pathophysiology, 1974, 549.
HARRIS, E. D., *editor*: Rheumatoid arthritis, 1974, 548.
HART, F. D., *editor*: The treatment of chronic pain, 1974. 116
HOLT, P. J. L., *editor*: Current topics in connective tissue diseases, 1975, 548.
HUSKISSON, E. C., and HART, F. DUDLEY: Joint disease: all the arthropathies, 2nd ed., 1975, 546.
MYLES, A. B. and DALY, J. R.: Corticosteroid and ACTH treatment: principles and problems, 1974. 378
OTAKA, Y., *editor*: Biochemistry and pathology of connective tissue, 1974, 549.
SERAFINI-FRACASSINI, A. and SMITH, J. W.: The structure and biochemistry of cartilage, 1974, 377
SWANSON, A. B.: Flexible implant resection arthroplasty in the hand and the extremities, 1973. 116
VELO, G. P., WILLOUGHBY, D. A., and GIROUD, J. P.: Future trends in inflammation, Proceedings of an International meeting on inflammation, Verona, June 28–30, 1973, 1974. 276
WILLIAMS, P. C.: Low back and neck pain. Causes and conservative treatment, 1974. 470
BOSSET, PH DE, *see* DE BOSSET, PH.
BOUSSINA, I., GERSTER, J. C., EPINEY, J., and FALLET, G. H. A study of the incidence of articular chondrocalcinosis in Paget's disease of bone, 198, *P*.
Bowel, chronic inflammatory disease of, psoriasis, and HL-A W27, *S1*/31
BRACKERTZ, D., HAGMANN, J., and KUEPPERS, F.: Proteinase inhibitors in rheumatoid arthritis, 225
Brain damage, chronic, ectopic calcification around joints of paralysed limbs, 499.
BRENNAN, J., *see* KENNEDY, A. C. *et al.*
BREWERTON, D. A.: HL-A 27 and acute anterior uveitis *S1*/33
—— *editor*: Symposium on histocompatibility and rheumatic disease, London, September 1974, supplement No 1, February 1975
—— *see also* NIKBIN, B. *et al.*
BREWIS, I., ELLIS, R. M., and SCOTT, J. T.: Single daily dose of allopurinol, 256
BREWIS, I. D. L., LOEBL, W. Y., and SCOTT, J. T.: Single daily dose of allopurinol, 201, *P*.
BOOKS, P., *see* KENNEDY, A. C. *et al.*
BROOKS, P. M., BELL, M. A., WALKER, J. J., KENNEDY, A. C., STURROCK, R. D., and DICK, W. C.: Ups and downs of indomethacin in bioavailability, 465, *P*.
—— *see also* ROONEY, P. J. *et al.*
SHARMA, J. N. *et al.*
BRUNEAU, C., EDMONDS, J. P., and HUGHES, G. R. V.: Circulating complexes and disease activity in SLE, 469, *P*.
—— *see also* EDMONDS, J. P. *et al.*
BUCHANAN, W. W., *see* KENNEDY, A. C. *et al.*
NUKI, G. *et al.*
WEBB, J. *et al.*
BUNCHER, C. R., *see* LINNEMANN, C. C. *et al.*
BUNN, D. N., MOSS, I. K., NICHOLLS, A., SCOTT, J. T., SNAITH, M. L., and WATSON, M. R.: Clinical and biochemical observations on three cases of hypoxanthine-guanine phosphoribosyltransferase deficiency, 249
BYERS, P.: Conclusions of a working party of morbid anatomists, international meeting, London, August 1974, *S2*/147
BYERS, P. D., and FOSS, M. V. L.: Bone density in osteoarthrosis, *S2*/130
—— ROPER, B. A., and GLENNIE, B.: Attempt to classify patients with arthritis of the hip suitable for prosthetic replacement, and their femoral heads, 298
BYROM, N., *see* NIKBIN, B. *et al.*
BYWATERS, E. G. L.: Obituary for J. GOSLINGS, 539
—— Symmetrical joint involvement; brief communication, 376
—— and WATSON, J.: Osteocyte in rheumatic diseases, *S2*/143
—— *see also* ROSENBERG, J. N. *et al.*

Caeruloplasmin and copper, plasma concentrations, rheumatoid arthritis, 162
Calcification, ectopic, around joints of paralysed limbs in hemiplegia, diffuse brain damage, and other neurological diseases, 499
Calcium and phosphate ions, equilibria, in articular cartilage, *S2*/46
CALIN, A.: Raised serum creatine phosphokinase activity in ankylosing spondylitis, 244
CAPERTON, E. M., BAKER, D. R., and KING, R.: Lymphocyte reactivity in rheumatoid arthritis. Mixed lymphocyte culture, 231
CAPSTICK, R. B., LEWIS, D. A., and COSH, J. A.: Naturally occurring anti-inflammatory factors in the synovial fluids of patients with rheumatic disease and their possible mode of action, 213
CARSON, D. W., *see* ROONEY, P. J. *et al.*
Cardiac lesions, Reiter's syndrome and ankylosing spondylitis, 195, *P*.
CARROLL, P., *see* LORBER, A. *et al.*
CASTLES, J. J., *see* SHAPIRO, R. F. *et al.*

Cathepsin D agglutinators, incidence in sera, synovial fluids, and exudate cells and synovial tissue in RA and other rheumatic diseases, 198, *P.*
CATS, A., LAFEBER, G. J. M., and KLEIN, F.: Immunoglobulin phagocytosis by granulocytes from sera and synovial fluids in various rheumatoid and non-rheumatoid diseases, 146
—— *see also* VAN DER LINDEN, J. M. J. P. *et al.*
CAULFIELD, J. B., *see* SWANN, D. A. *et al.*
Cellular immunity, defective in juvenile rheumatoid arthritis, 196, *P.*
—— —— impaired, in sero-negative arthritides, 203, *P.*
—— —— to synovial antigens in rheumatoid arthritis, 196, *P.*
Cerebrosides, synthesis, human articular cartilage, *S2*/62
CESELSKI, A., *see* SWANN, D. A. *et al.*
CHAMBERLAIN, M. A.: Behçet's disease, *S1*/53
—— and WRIGHT, V.: A double blind trial to assess the value of alclofenac compared with phenylbutazone in the management of rheumatoid arthritis, 186
Chang human liver cells in rheumatoid arthritis and other diseases, antibody-mediated leucocyte cytotoxicity, 544, *P.*
Chondrocalcinosis, articular, in Paget's disease of bone, incidence, 198, *P.*
—— familial, in the Chiloe Islands, Chile, 260
Chondrocytes, reversible transformation in degraded cartilage matrix to a fibroblast-like morphology, *S2*/146
—— sulphated proteoglycans and collagen, release and degradation from cell layer, *S2*/75
Chondroitin sulphate (ChS) chains, overlabelling after application of specific inhibitors of their biosynthesis, *S2*/61
Chromosomal damage and phenylbutazone, 409
CLARKE, A. K., VERNON-ROBERTS, B., and CURREY, H. L. F.: Assessment of anti-inflammatory drugs in the rat using subcutaneous implants of polyurethane foam impregnated with dead tubercle bacilli, 326
CLARKE, Sir C.: Panel discussion, histocompatibility and disease, *S1*/55
CLARKE, I. C., MIRRA, J., AMSTUTZ, H. C., Cartilage fibrillation versus ink-staining patterns, *S2*/12
Clustering, macrophage-lymphocyte, in rheumatoid arthritis, 38
Collagen, articular cartilage, action of rheumatoid synovial collagenase on, *S2*/71
—— —— —— nature and location of crosslinks, *S2*/41
—— —— —— biosynthesis in control and fibrillated, experimentally-induced osteoarthrosis, dog, *S2*/138
—— diseases, hyperbasophilic immunoblasts in circulating blood, 422
—— glycosaminoglycan interaction, articular cartilage, passive agglutination method, *S2*/38
—— intervertebral disc, in degenerative disc disease, 467, *P.*
—— pepsin-solubilized, chain composition, normal bovine and osteoarthrotic human articular cartilage, *S2*/35
—— and proteoglycan, breakdown in articular cartilage, organ culture, pig, 303
—— release and degradation from cell layer of human chondrocytes, *S2*/75
—— *see also* Procollagen
Collagenase, rheumatoid synovial, action on cartilage collagen, *S2*/71
COLLART, A. B., *see* ACHESON, R. M., and COLLART, A. B.
Complement activation in Reiter's syndrome, 468, *P.*
—— C3 and C4, behaviour in inflammatory and degenerative joint diseases before and after synoviorthesis, 166, 197, *P.*
—— —— inactivation products, raised levels in ankylosing spondylitis, 202, *P.*
—— level, *see also* Antibodies, antinuclear
Complexes, circulating and disease activity in SLE, 469, *P.*
—— —— *see also* Lupus erythematosus, systemic
Connective tissue disorders, and management of cardiac valvular disease, 321
—— —— matrices, immobilized, lubrication defect, *S2*/101
CONOCHIE, L., *see* SCOTT, J. E. *et al.*
CONSTINE, L., *see* SILVERMAN, S. *et al.*
Copper and caeruloplasmin, plasma concentrations, in rheumatoid arthritis, 162
—— excretion, urinary, in rheumatoid arthritis, 340
CORRESPONDENCE: National Case Register of less common rheumatic diseases, 275
COSH, J., *see* POOLE, A. R. *et al.*
COSH, J. A., GERBER, B., BARRITT, D. W., and JAYSON, M. I. V.: Cardiac lesions in Reiter's syndrome and ankylosing spondylitis, 195, *P.*
—— *see also* CAPSTICK, R. B. *et al.*
COVARRUBIAS, E., *see* REGINATO, A. J. *et al.*
CRACCHIOLO, A., *see* BACON, P. A. *et al.*
Creatine phosphokinase, raised serum activity in ankylosing spondylitis, 244
CUNNINGTON, P., *see* DAVIS, P. *et al.*
CURREY, H. L. F., *see* CLARKE, A. K. *et al.*
LIYANAGE, S. P. *et al.*
Cyclophosphamide therapy for rheumatoid disease, followed by myelomonocytic leukaemia, 534
Cysts, rheumatoid plantar synovial; case report, 98
—— wrist, and wrist fistulae, study of rheumatoid wrist, 388

D'AMBROSIA, R., *see* SHAPIRO, R. F. *et al.*
DANCEWICZ, A. M., *see* WIZE, J. *et al.*
DAVIDSON, C., WOJTULEWSKI, J. A., BACON, P. A., and WINSTOCK, D.: Temporo-mandibular joint disease in ankylosing spondylitis, 87, 468, *P.*
DAVIES, J. *see* DIXON, A. St. J. *et al.*
DAVIS, P., CUNNINGTON, P., and HUGHES, G. R. V.: Double-stranded RNA antibodies in systemic lupus erythematosus, 239
—— and HUGHES, G. R. V.: A serial study of eosinophilia and raised IgE antibodies during gold therapy, 203, *P.*
—— and JAYSON, M. I. V.: Acute knee joint rupture after yttrium 90 injection, 62
—— *see* BENTLEY, S. J. *et al.*
DAY, W. H., *see* SWANSON, S. A. V. *et al.*
DE BOSSET, PH, and BITTER, T.: Factors governing safety and success of gold salt therapy in rheumatoid arthritis (RA). A prospective study, 196, *P.*
DELBARRE, F., LE GÔ, A., and KAHAN, A.: Hyperbasophilic immunoblasts in circulating blood in chronic inflammatory rheumatic and collagen diseases, 422
—— *see also* REBUT-BONNETON, C. *et al.*

DEQUEKER, J.: Bone and ageing: Occasional survey, 100
DER KORST, J. K. VAN, *see* VAN DER KORST, J. K.
Diabetes, juvenile onset, and HL-A antigens, *S1*/42
DICK, H. M., *see* STURROCK, R. D. *et al.*
DICK, W. C., HILL, H., WRIGHT, V., and WOOD, P. H. N.: National Case Register of less common rheumatic diseases: correspondence, 275
—— *see also* BROOKS, P. M. *et al.*
GRENNAN, D. M. *et al.*
KENNEDY, A. C. *et al.*
SHARMA, J. N. *et al.*
STURROCK, R. D. *et al.*
WEBB, J. *et al.*
DIEPPE, P. A.: Empyema in rheumatoid arthritis, 181
DINGLE, J. T., HORSFIELD, P., FELL, H. B., and BARRATT, M. E. J.: Breakdown of proteoglycan and collagen induced in pig articular cartilage in organ culture, 303
—— *see also* POOLE, A. R. *et al.*
Disabled, equipment, booklet, 4th ed., 545
—— —— —— change of responsibility for publication, 276
Disc disease, degenerative, intervertebral disc collagen in, 467, *P.*
—— —— *see also* Lumbar disc disease
DISCHE, F. E., *see* SWINSON, D. R., *et al.*
Discography in assessment of lumbar disc disease, 466, *P.*
Disease predisposition, immune responsiveness, and fine structure of HL-A supergene, *S1*/17
DIXON, A. St. J. *chairman*: International Symposium on penicillamine, London, October 25 and 26 1974, report, 273
—— DAVIES, J., DORMANDY, T. L., HAMILTON, E. D. B., HOLT, P. J. L., MASON, R. M., THOMPSON, M., WEBER, J. C. P., ZUTSHI, D. W.: Synthetic D-penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen, 416
—— *see also* VIDIGAL, E. *et al.*
DNA antibodies, antinative, as a reaction to pyrazole drugs: case report, 373
—— binding capacity patterns in lupus nephritis, 444
—— polymerase activity in rheumatoid synovial membranes, 205
—— *see also* Antibodies, antinuclear
DORMANDY, T. L., *see* DIXON, A. St. J. *et al.*
MCMURRAY, W. *et al.*
DOWSON, D., WRIGHT, V., UNSWORTH, A., and GVOZDANOVIC, D.: An overall view of synovial joint lubrication, *S2*/94
—— *see also* GVOZDANOVIC, E. *et al.*
JOHNSON, G. R. *et al.*
SUCH, C. H. *et al.*
UNSWORTH, A. *et al.*
Drugs, anti-inflammatory and antirheumatic, actions on hexosamine biosynthesis, 200, *P.*
—— —— assessment, using subcutaneous implants of polyurethane foam impregnated with dead tubercle bacilli, 326
DUNCAN, A. M., *see* NUKI, G. *et al.*

EDMONDS, J. P., BRUNEAU, C., and HUGHES, G. R. V.: Assessment of activity in SLE: a clinical and serological study, 543, *P.*
—— *see also* BRUNEAU, C. *et al.*
EIBL, M. M., and SITKO, C.: MIF production of lymphocytes from patients with rheumatoid arthritis with antigen antibody complexes, 117
EISENSTEIN, R., SORGENTE, N., and KUETTNER, K. E.: Studies on cartilage vascularization, *S2*/76
—— *see also* KUETTNER, K. E. *et al.*
Elastic modulus, determination, articular cartilage, *S2*/116
Elbow, rheumatoid arthritis, joint involvement, and synovectomy with excision of radial head, 403
ELLIOTT, R. J., *see* GARDNER, D. L. *et al.*
ELLIS, R. M., *see* BREWIS, I. *et al.*
ELTEREN, PH. VAN, *see* VAN ELTEREN, PH.
Empyema in rheumatoid arthritis, 181
Enzymes in degradation of osteoarthrotic cartilage, *S2*/65
—— proteolytic, evidence of secretion from rheumatoid pannus and synovium, *S2*/71
Eosinophil-specific and other granulocyte-specific antinuclear antibodies in juvenile chronic polyarthritis and adult rheumatoid arthritis, 350, 468, *P.*
Eosinophilia and raised IgE antibodies during gold therapy, 203, *P.*
EPINEY, J., *see* BOUSSINA, I. *et al.*
Equipment for the disabled, 4th ed., 545
—— —— change of responsibility for publication of booklets, 276
Erbium and yttrium, radioactive colloids, effect of intra-articular injection on growth of rabbit legs, 529
ESIRI, M. M., *see* HAZLEMAN, B. L. *et al.*
EVANS, D. A. PRICE, *see* WALKER, S. *et al.*
EVANSON, J. M., *see* WOOLLEY, D. E. *et al.*
EYRE, D. R., MCDEVITT, C. A., and MUIR, H.: Experimentally-induced osteoarthrosis in the dog, *S2*/138

FABRY, G.: Early loss of glycosaminoglycans in experimental haemarthrosis in dogs, *S2*/142
FALLET, G. H., *see* BOUSSINA, I. *et al.*
GABAY, R. *et al.*
GERSTER, J. C. *et al.*
Fatigue testing in articular cartilage, *S2*/108
FAULK, W. P., *see* SCOTT, J. E., *et al.*
FEHR, K., ARTMANN, G., VELVART, M., and BONI, A.: Incidence of cathepsin D agglutinators in sera, synovial fluids, and exudate cells and synovial tissue of patients with RA and other rheumatic diseases, 198, *P.*
FELL, H. B., *see* DINGLE, J. T. *et al.*
POOLE, A. R. *et al.*
Felty's syndrome, granulopoietic activity, 156
Femoral head cartilage, osteoarthrotic, histological changes, *S2*/134
Feprazone, anti-inflammatory agent, potency and gastrointestinal tolerance, 190
FESSLER, J. H., and GREENBERG, G. M.: Procollagen of chick xyphoid cartilage, *S2*/40
FESTENSTEIN, H., and PEÑA-MARTINEZ, J.: Mixed lymphocyte reaction stimulating antigens, their detection, their relation to disease, and other markers of the major histocompatibility system, *S1*/7
Fibrils and proteoglycans, cartilage, interaction, *S2*/32
Fibroblasts, and synovial lining cells, proliferation, 219

FICAT, C., and MAROUDAS, A.: Cartilage of the patella. Typographical variation of glycosaminoglycan content in normal and fibrillated tissue, 515
—— Cartilage of the patella and its degeneration, *S2*/135
FICAT, P.: Contribution to the study of the initial stage of cartilage degeneration, *S2*/125
Fistulae, wrist, and wrist cysts, study of rheumatoid wrist, 388
Fistulization of rheumatoid joints, spectrum of identifiable syndromes, 489
FLETCHER, M. R., LOEBL, W., and SCOTT, J. T.: Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance, 190
—— and SCOTT, J. T.: Chronic monarticular synovitis. Diagnostic and prognostic features, 171
Fluid transport in cartilage, *S2*/77, *S2*/82
Foot in chronic rheumatoid arthritis, 292, 195, *P.*
FOSS, M. V. L., *see* BYERS, P. D., and FOSS, M. V. L.
FOX, A., and GLYNN, L. E.: Persistence of antigen in nonarthritic joints, 431
FRACASSINI, A. SERAFINI-, *see* SERAFINI-FRACASSINI, A.
FREEMAN, M. A. R.: Pathogenesis of osteoarthrosis: an hypothesis, *S2*/120
—— *see also* SWANSON, S. A. V. *et al.*
FREEMAN, W. D. S. C., and MAROUDAS, A.: Charged group behaviour in cartilage proteoglycans in relation to pH, *S2*/44
FRIDRICH, R., *see* PAVELKA, K. *et al.*
FROEBEL, K., *see* STURROCK, R. D. *et al.*

GABAY, R., MICHELI, A., and FALLET, G. H.: Behaviour of synovial complement C3 and C4 components in inflammatory and degenerative joint diseases, before and after synoviorthesis, 166, 197, *P.*
GABRIEL, R., *see* SCHWARTZ, E. R. *et al.*
GARDNER, D. L., ELLIOTT, R. J., GILMORE, R. St. C., and LONGMORE, R. B.: Microscopical appearance and organization of articular cartilage surfaces, *S2*/2
—— *see also* LONGMORE, R. B., and GARDNER, D. L.
Gene E_1^a, of serum cholinesterase, frequency in ankylosing spondylitis, 198, *P.*
GERBER, B., *see* COSH, J. A. *et al.*
GERSTER, J. C., HAUSER, H., and FALLET, G. H.: Xeroradiographic technique applied to assessment of Achilles tendon in inflammatory or metabolic diseases, 479
—— *see also* BOUSSINA, I. *et al.*
GHADIALLY, F. N., and ORYSCHAK, A. F.: Sequential changes in superficial defects in articular cartilage studied with scanning electron microscopy, *S2*/8
GHOSH, P., STEPHENS, R., and TAYLOR, T. K. F.: Mechanism of cartilage and synovial fluid hyaluronate degradation by polysaccharidases, *S2*/73
GILBERTSON, E. M. M.: Development of periarticular osteophytes in experimentally induced osteoarthritis in the dog. A study using microradiographic, microangiographic, and fluorescent bone-labelling techniques, 12
—— *see also* MCDEVITT, C. A. *et al.*
GILMORE, R. St. C., *see* GARDNER, D. L. *et al.*
GLANVILLE, R. W., *see* WOOLLEY, D. E. *et al.*
GLASS, D. N., *see* HOLIAN, J. *et al.*
GLENNIE, B., *see* BYERS, P. D. *et al.*
Glycosaminoglycans, articular cartilage, biosynthesis, nucleotide sugar metabolism, *S2*/48
—— —— —— concentration, distribution, and metabolism, *S2*/42
—— —— —— distribution and synthesis, effect of *in vitro* incubation, *S2*/58
—— —— —— early loss in experimental haemarthrosis, dogs, *S2*/142
—— —— —— content, topographical content in normal and fibrillated tissue of patella cartilage, 515
—— urinary acid, circadian rhythms in excretion, *S2*/63
—— variation of content, patella degeneration, *S2*/135
—— variations with surface site human knee joint cartilage, *S2*/44
GLYNN, L. E., *see* FOX, A., and GLYNN, L. E.
Gold therapy, safety and success in rheumatoid arthritis, 196, *P.*
—— —— eosinophilia and raised IgE antibodies during, 203, *P.*
GOLDBERG, L., *see* WEBB, F. W. S. *et al.*
GOLDBERG, L. S. *see* BACON, P. A. *et al.*
BLUESTONE, R. *et al.*
GOLDING, D. N., and WALSHE, J. M.: The musculoskeletal features of Wilson's disease: a clinical, radiological, and serological survey, 201, *P.*
GOODE, J. D., *see* MOLL, J. M. H. *et al.*
GOODFELLOW, J. W., *see* PASION, E. G., and GOODFELLOW, J. W.
GOSLINGS, J., 1903–1975, Obituary (Bywaters), 539
GRAHAME, R., *see* SILVERMAN, S. *et al.*
Granulopoietic activity in Felty's syndrome, 156
GRAYSON, M. F., MARTIN, V. M., and MARKHAM, R. L.: Antinative DNA antibodies as a reaction to pyrazole drugs: case report, 373
GREEN, R., *see* POOLE, A. R. *et al.*
GREENBERG, G. M., *see* FESSLER, J. H., and GREENBERG, G. M.
GREENWOOD, B. M., *see* OKAFOR, G. O. *et al.*
GRENNAN, D. M., ZEITLIN, I. J., MITCHELL, W. S., and DICK, W. C.: Effects of prostaglandins PGE_1, PGE_2, $PGF_{1\gamma}$ and $PGF_{2\gamma}$ on the synovial microcirculation, 540, *P.*
—— *see also* ROONEY, P. J. *et al.*
GREY, G., *see* KENNEDY, A. C. *et al.*
GRIFFITHS, I. D., *see* HOLIAN, J. *et al.*
Growth hormone, response of articular cartilage in organ culture to, *S2*/74
GUPTA, R., ROBINSON, W. A., and ALBRECHT, D.: Granulopoietic activity in Felty's syndrome, 156
GVOZDANOVIC, D., WRIGHT, V., and DOWSON, D.: Formation of lubricating monolayers at the cartilage surface, *S2*/100
—— *see also* DOWSON, D. *et al.*

Haemangioma, cavernous, lip and pulmonary stenosis, associated with pigmented villonodular synovitis in multiple joints: case report, 269
Haemarthrosis, experimental, glycosaminoglycans, early loss, dogs, *S2*/142
HAGMANN, J., *see* BRACKERTZ, D. *et al.*

HALIM, W., VAN DER KORST, J. K., VALKENBURG, H. A., and VAN ELTEREN, PH.: Terminal phalangeal osteosclerosis, 82, 201, *P.*
HALL, B. K.: Differentiation and maintenance of articular (secondary) cartilage on avian membrane bones, *S2*/145
HALL, M. A., ANSELL, B. M., JAMES, D. C. O., and ZYLINSKI, P.: HL-A antigens in juvenile chronic polyarthritis (Still's disease), *S1*/36
HALLIDAY, L. D. C., *see* WALKER, S. *et al.*
HALONEN, P., *see* KALLIOMÄKI, J. L. *et al.*
HAMILTON, E. D. B., *see* DIXON, A. St. J. *et al.*
SWINSON, D. R. *et al.*
HAMPSON, W. G., *see* SHAH, J. S. *et al.*
HANCOCK, J. A. H., *see* IVESON, J. M. I. *et al.*
HARDINGHAM, T. E.: Biosynthesis of proteoglycans in cartilage, *S2*/52
—— and MUIR, H.: Structure and stability of proteoglycan aggregates, *S2*/26
HARVEY, W., *see* SILVERMAN, S. *et al.*
HAUSER, H., *see* GERSTER, J. C. *et al.*
HAZLEMAN, B. L., MACLENNAN, I. C. M., and ESIRI, M. M.: Lymphocyte proliferation to artery antigen as a positive diagnostic test in polymyalgia rheumatica, 122, 203, *P.*
HEBERDEN SOCIETY: Annual General Meeting, November 1 and 2 1974, report and proceedings, 461
—— —— Clinical Meetings, Bristol, June 1974, 195; Manchester, 1974, 200, Norwich, March 1975, 540
—— —— Symposium, London, September 1974, 116
HECHT, B., *see* ADLER, M. K. *et al.*
HEINEGÅRD, D.: Structure of cartilage proteoglycans, *S2*/29
HEMBRY, R. M., *see* POOLE, A. R. *et al.*
Hemiplegia, ectopic calcification around joints of paralysed limbs, 499
HENDERSON, D. R. F., JAYSON, M. I. V., and TRIBE, C. R.: Lack of correlation of synovial histology with joint damage in rheumatoid arthritis, 7, 199, *P.*
HENDERSON, N., *see* STURROCK, R. D. *et al.*
HERBAGE, D.: Chain composition of pepsin-solubilized collagen from normal bovine and osteoarthrotic human articular cartilage, *S2*/35
HERBERT, C. M., LINDBERG, K. A., JAYSON, M. I. V., and BAILEY, A. J.: Intervertebral disc collagen in degenerative disc disease, 467, *P.*
Hexosamine biosynthesis, actions of some anti-inflammatory and antirheumatic drugs, 200, *P.*
HIGGINSON, G. R., and LITCHFIELD, M. R.: A simple mechanical model of articular cartilage, *S2*/115
HIGHTON, T. C., *see* MIDDLETON, P. J., and HIGHTON, T. C.
HILL, A. G. S., *see* IVESON, J. M. I. *et al.*
HILL, H., *see* DICK, W. C. *et al.*
HILL, V., *see* LORBER, A. *et al.*
HILTON, R. C., and BALL, J.: Mobility, end-plate defects and disc degeneration in the lower spine, 201, *P.*
Hip, arthritis, classification of patients suitable for prosthetic replacement, and their femoral heads, 298
—— human cadaver, loaded, contact pressures, *S2*/114
HL-A 27 and acute anterior uveitis, *S1*/33
—— and ankylosing spondylitis, *S1*/1
—— —— —— family study, *S1*/53
—— in reactive arthritis following infection, *S1*/29
—— and Reiter's disease, *S1*/27
HL-A antigens, disease associations, family studies *S1*/42
—— —— identification by serological criteria, *S1*/4
—— —— in juvenile polyarthritis (Still's disease), *S1*/36
HL-A supergene, fine structure, and disease predisposition and immune responsiveness, *S1*/17
HL-A system and its association with immune response and disease, *S1*/13
—— W27-positive rheumatic disease, aberrant immunity, *S1*/46
HL-A W27 and the spondylitis of chronic inflammatory bowel disease and psoriasis *S1*/31
HOBBS, J. R., *see* NIBKIN, B. *et al.*
HOLBOROW, E. J., *see* BLUESTONE, R. *et al.*
JOHNSON, G. D. *et al.*
ROSENBERG, J. N. *et al.*
HOLIAN, J., GRIFFITHS, I. D., GLASS, D. N., MAINI, R. N., and SCOTT, J. T.: Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus, 438
HOLLANDER, J. L., *see* REGINATO, A. J. *et al.*
HOLT, P. J. L., *see* DIXON, A. St. J. *et al.*
HOOFF, J. P. VAN, *see* VAN HOOFF, J. P.
HORSFIELD, P. *see* DINGLE, J. T. *et al.*
HOWARD, A., ANSELL, B. M., and POWELL, R.: Immunoglobulin levels during rubella in children suffering from Still's disease, 204, *P.*
HOWELL, D. S., *see* KUETTNER, K. E. *et al.*
HUCKELL, J. R., *see* LESZCZYNSKI, J. *et al.*
HUGHES, G. R. V., *see* BRUNEAU, C. *et al.*
DAVIS, P., and HUGHES, G. R. V.
DAVIS, P. *et al.*
EDMONDS, J. P. *et al.*
HUMBERSTONE, P. M., *see* MOLL, J. M. H. *et al.*
Hyaluronic acid, proteins associated with, *S2*/98
Hyaluronidase, and antiproteoglycan serum, effect on metabolic functions of calf cartilage cell *in vitro*, *S2*/59
—— degradation of cartilage and synovial fluid by polysaccharidases, *S2*/73
Hypertension in relation to musculoskeletal disorders, 451
Hypoxanthine-guanine phosphoribosyltransferase deficiency, clinical and biochemical observations, three cases, 249

Illustration, graphic, in handbooks for patients, 542, *P.*
Immune response, disease predisposition, and fine structure of HL-A supergene, S1/17
—— and the HL-A system and disease, S1/13
Immunoblasts, hyperbasophilic, in circulating blood in chronic inflammatory rheumatic and collagen diseases, 422
Immunoglobin E antibodies, raised, and eosinophilia, during gold therapy, 203, *P.*
—— levels during rubella in children with Still's disease, 204, *P.*
—— phagocytosis by granulocytes, rheumatoid and non-rheumatoid diseases, 146
Indomethacin, response of plasma kininogen levels in rheumatoid arthritis to, relationship to clinical indices, 464, *P.*
—— ups and downs in bioavailability, 465, *P.*
INOUE, H., and KODAMA, T.: Three-dimensional observations of articular cartilage matrix, *S2*/21

International Rheumatology Meeting, Israel, April 25–27, 1976, announcement, 545
—— Symposium on penicillamine, London, October 25 and 26 1974, report, 273
IONESCU, M., *see* IVESON, J. M. I. *et al.*
IVESON, J. M. I., HILL, A. G. S., and WRIGHT, V.: Wrist cysts and fistulae. An arthrographic study of the rheumatoid wrist, 388
—— NANDA, B. S., HANCOCK, J. A. H., POWNALL, P. J., and WRIGHT, V.: Reiter's disease in three boys, 364
—— THADANI, U., IONESCU, M., and WRIGHT, V.: Aortic valve incompetence and replacement in rheumatoid arthritis, 312, 464, *P.*

JACOBELLI, S., *see* REGINATO, A. J. *et al.*
JACOBY, R. K., *see* VIDIGAL, E. *et al.*
JAMES, D. C. O.: Ankylosing spondylitis and HL-A 27, *S1*/1
—— *see* HALL, M. A. *et al.*
NIKBIN, B. *et al.*
JASANI, M. K., *see* KENNEDY, A. C. *et al.*
JAYSON, M. I. V.: Report on International Symposium on penicillamine, London, October 25 and 26, 1974, 273
—— *see also* BENTLEY, S. J. *et al.*
COSH, J. A. *et al.*
DAVIS, P., and JAYSON, M. I. V.
HENDERSON, D. R. F. *et al.*
HERBERT, C. M. *et al.*
O'DRISCOLL, S. L., and JAYSON, M. I. V.
SHAH, J. S. *et al.*
JEFFREY, M. R., *see* MOLL, J. M. H. *et al.*
JENNINGS, J.: Defective cellular immunity in juvenile rheumatoid arthritis, 196, *P.*
JEUNING, J. J., *see* VAN ROOD, J. J. *et al.*
JOHNSON, G. D., ONYEWOTU, I. I., and HOLBOROW, E. J.: Relationship between antinuclear antibodies, DNA binding capacity and electroprecipitation, serum complement level, and the presence of soluble complexes in systemic lupus erythematosus and rheumatoid arthritis, 469, *P.*
—— *see also* ROSENBERG, J. N. *et al.*
JOHNSON, G. R., DOWSON, D., and WRIGHT, V.: A new approach to the determination of the elastic modulus of articular cartilage, *S2*/116
Joint(s), damage, in rheumatoid arthritis, lack of correlation of synovial histology, 7, 199, *P.*
—— diseases, behaviour of synovial complement C3 and C4 components before and after synoviorthesis, 166, 197, *P.*
—— and rheumatoid synovitis, relationship between arthroscopic and histological changes, 1, 464, *P.*
—— formation in culture, 200, *P.*
—— knee, stiffness, quantitative study, 286
—— lubrication, exact mechanisms, new evidence, 277
—— mobility, and *in vivo* skin elasticity, survey in London schoolchildren, 177
—— morbidity, uric acid and streptococcal antibodies in Maori and European teenagers, Rotorua lakes study 3, 359
—— nonarthritic, persistence of antigen in, 431
—— rheumatoid, fistulization, spectrum of identifiable syndromes, 489
—— symmetrical involvement: brief communication, 376
JONES, I. L., *see* LEMPERG, R. K. *et al.*
JUTTLA, G., and WRIGHT, V.: Mark Twain and rheumatology, 466, *P.*

KAHAN, A., *see* DELBARRE, F. *et al.*
KALLIOMÄKI, J. L., HALONEN, P., and SALMI, A.: Virus antibodies in serum and synovial fluid of patients with rheumatoid arthritis and other connective tissue diseases, 43
KEMPSON, G. E.: Mechanical properties of articular cartilage and their relationship to matrix degradation and age, *S2*/111
—— MAROUDAS, A., and WEIGHTMAN, B. *editors*: Articular cartilage, Symposium, Supplement 2, December 1975
KENNEDY, A. C., BRENNAN, J., ANDERSON, J., BROOKS, P., BUCHANAN, W. W., and DICK, W. C.: Serum uric acid—its relationship to lean body mass, sex, plasma urea, intracellular potassium and packed cell volume in a normal population group, 543, *P.*
—— SMITH, D. A., GREY, G., JASANI, M. K., and BUCHANAN, W. W.: Osteoporosis in patients with rheumatoid arthritis, 542, *P.*
—— LEE, P., DICK, W. C., and BUCHANAN, W. W.: Plasma zinc in rheumatoid arthritis. Its relationship to corticosteroid therapy and osteoporosis, 201, *P.*
—— *see also* BROOKS, P. M. *et al.*
NUKI, G. *et al.*
KEUNING, J. J., *see* VAN DER LINDEN, J. M. J. P. *et al.*
KHALAF, A. A., *see* WILCOX, W. R., and KHALAF, A. A.
KING, P., *see* NUKI, G. *et al.*
KING, R., *see* CAPERTON, E. M. *et al.*
Kininogen, raised plasma levels, in rheumatoid arthritis, response to indomethacin and relationship to clinical indices, 464, *P.*
KIRKUP, J., *see* VIDIGAL, E. *et al.*
KLEIN, F., *see* CATS, A. *et al.*
KLEINE, T. O., and STEPHAN, R.: Overlabelling of chondroitin sulphate (ChS) chains after application of specific inhibitors of their biosynthesis, *S2*/61
—— and WUNSCH, M.: Effect of antiproteoglycan serum and hyaluronidase on metabolic functions of calf cartilage cells *in vitro*, *S2*/59
Knee joint, menisci, load bearing function, *S2*/118
—— rupture, acute, after yttrium 90 injection, 62
—— stiffness, quantitative study, 286
—— tissues, effects of colloidal yttrium 90, histological studies, rabbits, 64
KODOMA, T., *see* INOUE, H., and KODOMA, T.
KORST, J. K. VAN DER, *see* VAN DER KORST, J. K.
KSIEZNY, S., *see* WIZE, J. *et al.*
KUEPPERS, F., *see* BRACKERTZ, D. *et al.*
KUETTNER, K. E., PITA, J. C., HOWELL, D. S., SORGENTE, N., and EISENSTEIN, R.: The possible function of lysosyme in cartilage metabolism, *S2*/69
—— *see also* EISENSTEIN, R. *et al.*

LAFEBER, G. J. M., *see* CATS, A. *et al.*
LANCE, E. M., *see* LOEWI, G. *et al.*
LARSSON, S.-E., and LEMPERG, R. K.: Concentration, distribution, and metabolism of glycosaminoglycans in different layers of normal human articular cartilage, *S2*/42
—— *see also* LEMPERG, R. K. *et al.*

LASSUS, A.: Circinate erosive balanitis, *S1*/54
—— *see* AHO, K. *et al.*
LAWRENCE, J. S.: Hypertension in relation to musculoskeletal disorders, 451
LEE, P., *see* KENNEDY, A. C. *et al.*
LEEB, J., *see* LORBER, A. *et al.*
LEGÔ, A., *see* DELBARRE, F. *et al.*
LEMPERG, R., *see* SMITH, T. W. D. *et al.*
LEMPERG, R. K., LARSSON, S.-E., and JONES, I. L.: Effect of *in vitro* incubation on distribution and synthesis of glycosaminoglycans of articular cartilage, *S2*/58
—— *see also* LARSSON, S.-E., and LEMPERG, R. K.
LENTLE, B. C., *see* LESZCZYNSKI, J. *et al.*
LERICHE, J. C., *see* LESZCZYNSKI, J. *et al.*
LESZCZYNSKI, J., HUCKELL, J. R., PERCY, J. S., LERICHE, J. C., and LENTLE, B. C.: Pigmented villonodular synovitis in multiple joints. Occurrence in a child with cavernous haemangioma of lip and pulmonary stenosis: case report, 269
Leucocyte(s), polymorphonuclear, phagocytosis of urate crystals by, 54
—— procollagenase, human, activation by rheumatoid synovial tissue culture medium, 520
Leukaemia, myelomonocytic, following cyclophosphamide therapy of rheumatoid disease, 534
LEVINSON, J. E., *see* LINNEMANN, C. C. *et al.*
LEWIS, D. A., *see* CAPSTICK, R. B. *et al.*
LINDBERG, K. A., *see* HERBERT, C. M. *et al.*
WOOLLEY, D. E. *et al.*
LINDEN, J. M. J. P. VAN DER, *see* VAN DER LINDEN, J. M. J. P.
LINNEMANN, C. C., LEVINSON, J. E., BUNCHER, C. R., and SCHIFF, G. M.: Rubella antibody levels in juvenile rheumatoid arthritis, 354
LIPSCOMB, P. R., *see* SHAPIRO, R. F. *et al.*
LITCHFIELD, M. R., *see* HIGGINSON, G. R., and LITCHFIELD, G. R.
LITTLER, T. R., *see* WALKER, S. *et al.*
Liver disease in rheumatoid arthritis and Sjøgren's syndrome, 70
—— function tests and liver biopsies in rheumatic arthritis, 198, *P.*
LIYANAGE, S. P., CURREY, H. L. F., and VERNON-ROBERTS, B.: Influence of tubercle aggregate size on severity of adjuvant arthritis in the rat, 49
Load bearing function, knee joint menisci, *S2*/118
LOEBL, W., *see* FLETCHER, M. R. *et al.*
LOEBL, W. Y., *see* BREWIS, I. D. L. *et al.*
LOEWI, G., LANCE, E. M., and REYNOLDS, J.: Study of lymphoid cells from inflamed synovial membranes, 524
LONGMORE, R. B., and GARDNER, D. L.: Development with age of human articular cartilage surface structure. A survey by interference microscopy of the lateral femoral condyle, 26
—— *see also* GARDNER, D. L. *et al.*
LORBER, A., LEEB, J., CARROLL, P., BAUMGARTNER, W., and HILL, V.: Protein sulphydryl depression during adjuvant arthritis, 346
LOVE, R. R., and SOWA, J. M.: Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease, 534
Lubricant, articular, purification and properties, *S2*/91
Lubricating monolayers, formation at cartilage surfaces, *S2*/100
Lubrication defect of immobilized connective tissue matrices, *S2*/101
—— joint, exact mechanism, new evidence, 277
—— —— overall view, *S2*/94
——, weeping, *see* Weeping lubrication
LUKASIK, E. WOJTECKA-, *see* WOJTECKA-LUKASIK, E.
Lumbar discs, biochemical studies, 467, *P.*
—— —— disease, discography in assessment, 466, *P.*
Lupus erythematosus, double-stranded RNA antibodies, 239
—— systemic, anti-DNA antibody reference standards for diagnosis and management, 438
—— —— —— assessment of activity, 543, *P.*
—— —— —— circulating complexes and disease activity in, 469, *P.*
—— —— —— relationship between antinuclear antibodies, DNA binding capacity, electroprecipitation serum complement level, and the presence of soluble complexes in, 469, *P.*
—— nephritis, prognostic significance of DNA-binding capacity patterns in, 444
Lymphocyte(s) function in ankylosing spondylitis, *S1*/49
—— MIF production, in rheumatoid arthritis with antigen-antibody complexes, 117
—— proliferation to artery antigen, diagnostic test in polymyalgia rheumatica, 122, 203, *P.*
—— reactivity in rheumatoid arthritis, mixed lymphocyte culture, 231
—— *see also* Mixed lymphocyte reaction
Lymphoid cells from inflamed synovial membranes, 524
Lysozyme, in cartilage metabolism, function, *S2*/69
MCCUTCHEN, C. W.: An approximate equation for weeping lubrication, solved with an electrical analogue, *S2*/85
MCDEVITT, C. A., and MUIR, H.: Proteoglycan aggregation in early experimental osteoarthrosis, *S2*/137
—— —— and GILBERTSON, E. M. M.: Impairment of proteoglycan-collagen interaction in early experimental osteoarthrosis, 541, *P.*
—— *see also* EYRE, D. R. *et al.*
MCGAVIN, D. D. M., *see* ROONEY, P. J. *et al.*
MACLENNAN, I. C. M., *see* HAZLEMAN, B. L. *et al.*
MCLEOD, L., *see* NIKBIN, B. *et al.*
MCMURRAY, W., MARTIN, V. M., SCUDDER, P., STOCKS, J., WHITE, A. G., and DORMANDY, T. L.: Urinary copper excretion in rheumatoid arthritis, 340
MACSWEEN, R. N. M., *see* STURROCK, R. D. *et al.*
WEBB, J. *et al.*
MAINI, R. N., *see* HOLIAN, J. *et al.*
YATES, D. B. *et al.*
MALKA, S., *see* NIKBIN, B. *et al.*
MANNERS, J., *see* MULHOLLAND, R. *et al.*
Maori and European teenagers, uric acid, joint morbidity and streptococcal antibodies, Rotorua lakes study 3, 359
MARCELON, G.: Ultrastructural and histological studies on articular cartilage in experimental osteoarthritis, *S2*/136
Mark Twain, and rheumatology, 466, *P.*

MARKHAM, R. L., *see* GRAYSON, M. F. *et al.*
MARMION, B. P., *see* NORVAL, M. *et al.*
MAROUDAS, A.: Cartilage turnover, *S2*/55
—— Fluid transport in cartilage, *S2*/77
—— *see also* BENDERLY, H., and MAROUDAS, A.
FICAT, C., and MAROUDAS, A.
FREEMAN, W. D. S. C., and MAROUDAS, A.
KEMPSON, G. E. *et al.*
MARTIN, V. M., *see* GRAYSON, M. F. *et al.*
McMURRAY, W. *et al.*
MARTINEZ, J. PEÑA-, *see* PEÑA-MARTINEZ, J.
MARTINEZ, V., *see* REGINATO, A. J. *et al.*
MASON, R. M., *see* DIXON, A. St. J. *et al.*
MATTHEWS, J. V., *see* AKESON, W. H. *et al.*
MEACHIM, G.: Articular cartilage lesions in the Liverpool population, *S2*/122
MEIER-RUGE, W., *see* PAVELKA, K. *et al.*
Membrane bones, avian, on articular cartilage, differentiation and maintenance, *S2*/145
MERKER, H. J., *see* RAJAN, K. T., and MERKER, H. J.
METZGER, A. L., *see* BLUESTONE, R. *et al.*
MEUNIER, P., *see* VIGNON, E. *et al.*
MICHELI, A.: Frequency of the atypical gene E_1^a of serum cholinesterase among patients with ankylosing spondylitis, 198, *P.*
—— *see also* GABAY, R. *et al.*
MIDDLETON, P. J., and HIGHTON, T. C.: Failure to show mycoplasmas and cytopathogenic virus in rheumatoid arthritis, 369
Migration inhibition factor production of lymphocytes in rheumatoid arthritis with antigen-antibody complexes, 117
MILLINGTON, P. F., *see* MULHOLLAND, R. *et al.*
MIRRA, J., *see* CLARKE, I. C. *et al.*
MITCHELL, W. S., *see* GRENNAN, D. M. *et al.*
MITROVIC, D.: Some new morphological data on histogenesis of articular cartilage, *S2*/19
Mixed lymphocyte reaction stimulating antigens, *S1*/7
Mobility, end-plate defects, and disc degeneration on lower spine, 201, *P.*
MOHING, W., *see* MOHR, W. *et al.*
MOHR, W., BENEKE, G., and MOHING, W.: Proliferation of synovial lining cells and fibroblasts, 219
MOLL, J. M. H., WRIGHT, V., JEFFREY, M. R., GOODE, J. D., and HUMBERSTONE, P. M.: Graphic illustration in handbooks for patients, 542 *P.*
Monarticular synovitis, chronic, diagnostic and prognostic features, 171
Monocytes, steroid-treated, stimulation of polymorph migration by a factor produced by, 202, *P*,
Monosodium urate crystals, nucleation, 332
MORRIS, R. I., *see* BLUESTONE, R. *et al.*
MOSS, I. K., *see* BUNN, D. N. *et al.*
MOW, V. C., and TORZILLI, P. A.: Fundamental fluid transport mechanisms through articular cartilage, *S2*/82
MUIR, H., *see* ADAMS, P., and MUIR, H.
EYRE, D. R. *et al.*
HARDINGHAM, T. E., and MUIR, H.
McDEVITT, C. A., and MUIR, H.
McDEVITT, C. A. *et al.*
MULHOLLAND, R., MILLINGTON, P. F., and MANNERS, J.: Some aspects of the mechanical behaviour of articular cartilage, *S2*/104
MÜLLER, W., *see* PAVELKA, K. *et al.*
Musculoskeletal disorders, in relation to hypertension, 451
Mycoplasmas and cytopathogenic virus, failure to show in rheumatoid arthritis, 369

NANDA, B. S., *see* IVESON, J. M. I. *et al.*
NATIONAL FUND FOR RESEARCH INTO CRIPPLING DISEASES: Equipment for the disabled, change of responsibility for publication of booklets, 276
National Register on Intra-articular Isotopes, notice, 378
Negro, South African, rheumatoid arthritis, 463, *P.*
Nephropathy, penicillamine, 544, *P.*
Neurofibrosarcoma following radiotherapy for ankylosing spondylitis, 536
NEWTON, D., *see* SCOTT, J. E., and NEWTON, D.
NICHOLLS, A.: Reiter's disease and HL-A 27, *S1*/27
—— *see also* BUNN, D. N. *et al.*
NIKBIN, B., BREWERTON, D. A., BYROM, N., JAMES, D. C. O., MALKA, S., McLEOD, L., SLATER, L., WARREN, R. E., and HOBBS, J. R.: Lymphocyte function in ankylosing spondylitis, *S1*/49
NIWAYAMA, G., *see* SHAPIRO, R. F. *et al.*
NORVAL, M., OGILVIE, M. M., and MARMION, B. P.: DNA polymerase activity in rheumatoid synovial membranes, 205
NUKI, G., BODDY, K., KENNEDY, A. C., KING, P., DUNCAN, A. M., and BUCHANAN, W. W.: Potassium metabolism in patients with rheumatoid arthritis. Effects of treatment with depot tetracosactrin, spironolactone, and oral supplements of potassium chloride, 506
—— *see also* WEBB, J. *et al.*

O'DRISCOLL, S. L., and JAYSON, M. I. V.: Pain threshold (PT) analysis in patients with osteoarthritis of the hip, 195, *P.*
OGILVIE, M. M., *see* NORVAL, M. *et al.*
OKAFOR, G. O., TURNER, M. W., and GREENWOOD, B. M.: Antiglobulins in Nigerians with rheumatoid disease, 142
ONYEWOTO, I. I., *see* JOHNSON, G. D. *et al.*
ORYSCHAK, A. F., *see* ORYSCHAK, A. F., and GHADIALLY, F. N.
Osteoarthritis, experimentally induced, development of periarticular osteophytes, dog, 12
—— generalized, problem of definition, 466, *P.*
—— hip, pain threshold analysis, 195, *P.*
Osteoarthrosis, bone density, *S2*/130
—— enzymes in degradation, *S2*/65
—— experimental, articular cartilage, ultrastructure and histology, *S2*/136
—— —— collagen biosynthesis, *S2*/138
—— —— early, impairment of proteoglycan-collagen interaction, 541, *P.*
—— —— —— proteoglycan aggregation, *S2*/137
—— in femoral head cartilage, histological changes, *S2*/134
—— mechanical factors, aetiology, *S2*/132
—— pathogenesis, *S2*/120
—— —— conclusions of a working party, international meeting, London, August 1974, *S2*/147
—— —— —— SEM, *S2*/23

—— and some systemic characteristics in general population, relationship between. New Haven survey of joint diseases, XVII. 379
—— ultrastructural aspects, *S2*/21
Osteocyte death in rheumatic disease, *S2*/143
Osteophytes, periarticular, development in experimentally induced osteoarthritis, dog, 12
Osteoporosis, in patients with rheumatoid arthritis, 542, *P.*
Osteosclerosis, terminal phalanges, 82, 201, *P.*

Paget's disease of bone, incidence of articular chondrocalcinosis, 198, *P.*
Pain threshold analysis in osteoarthritis of hip, 195, *P.*
PALFREY, A. J.: Matrix structure in articular cartilage, *S2*/20
PALMER, D. G.: Relationships between rheumatoid cells in culture, 235
PANAYI, G. S.: Antibody-mediated leucocyte cytotoxicity to Chang human liver cells in rheumatoid arthritis and other diseases, 544 *P.*
PASION, E. G., and GOODFELLOW, J. W.: Pre-ankylosing spondylitis: histopathological report, 92
Patella, articular cartilage, degeneration, *S2*/135
—— —— —— topographical variation of glycosaminoglycan content in normal and fibrillated tissue, 515
PATTON, J. T.: Discography in assessment of lumbar disc disease, 466, *P.*
PAUL, I. L., *see* RADIN, E. L. *et al.*
PAVELKA, K., MEIER-RUGE, W., MÜLLER, W., and FRIDRICH, R.: Histological study of effects of colloidal 90 yttrium on knee joint tissues of rabbits, 64
PEÑA-MARTINEZ, J., *see* FESTENSTEIN, H., and PEÑA-MARTINEZ, J.
Penicillamine, D-, synthetic, in rheumatoid arthritis, double-blind controlled study, high and low dosage, 416
—— International Symposium, London, October 25 and 26, 1974, report, 273
—— nephropathy, 544, *P.*
PERCY, J. S., *see* LESZCZYNSKI, J., *et al.*
PFENNINGER, K., *see* RAU, R. *et al.*
Phalangeal osteosclerosis, terminal phalanges, 82, 201, *P.*
PHELPS, C., and STEVENS, R.: Nucleotide sugar metabolism in glycosaminoglycan biosynthesis, *S2*/48
PHELPS, C. F., *see* WINTERBURN, P. J., and PHELPS, C. F.
Phenylbutazone and chromosomal damage, 409
—— compared with alclofenac, double blind trial in rheumatoid arthritis, 186
Phosphate and calcium ions, equilibria, in articular cartilage, *S2*/46
PINDER, I., *see* POOLE, A. R. *et al.*
PITA, J. C., *see* KUETTNER, K. E. *et al.*
Polyarthritis, juvenile chronic (Still's disease) and adult rheumatoid arthritis, eosinophil specific and granulocyte-specific antinuclear antibodies in, 350, 468, *P.*
—— —— —— and HL-A antigens, *S1*/36
Polymorph migration, stimulation by a factor produced by steroid-treated monocytes, 202, *P.*
Polymyalgia rheumatica, lymphocyte proliferation to artery antigen as diagnostic test, 122, 203, *P.*
POOLE, A. R., FELL, H. B., BARRATT, M. E. J., WELLAND, H., and GREEN, R.: Immunocytochemical and histochemical studies of a reversible transformation of chondrocytes in degraded cartilage matrix to a fibroblast-like morphology, *S2*/146
—— HEMBRY, R. M., DINGLE, J. T., PINDER, I., COSH, J., and RING, F. J.: Evidence for secretion of a proteolytic enzyme from rheumatoid pannus and synovium, *S2*/71
Potassium metabolism in rheumatoid arthritis, effects of depot tetracosactrin, spironolactone and oral supplements of potassium chloride, 506
POWELL, R., *see* HOWARD, A. *et al.*
POWNALL, P. J., *see* IVESON, J. M. I., *et al.*
Pre-ankylosing spondylitis, histopathological report, 92
Predisposition, disease, immune responsiveness, and fine structure of HL-A supergene, *S1*/17
Pressures, contact, in loaded cadaver human hip, *S2*/114
PRICE EVANS, D. A., *see* EVANS, D. A. PRICE
PRIOR, I. A. M., *see* STANHOPE, J. M., and I. A. M. PRIOR
Proceedings, Heberden Society, Annual General Meeting, November 1 and 2, 1974, 461; clinical meeting, Bristol, June 1974, 195; clinical meeting, Manchester, September 1974, 200, Norwich, March 1975, 540
Procollagen, of chick xyphoid cartilage, *S2*/40
Prostaglandins, effects on synovial microcirculation, 540, *P.*
Prosthetic replacement, classification of patients with hip arthritis suitable for, 298
Proteinase inhibitors in rheumatoid arthritis, 225
Proteins associated with hyaluronic acid, *S2*/98
—— sulphydryl depression during rheumatoid arthritis, 346
Proteoglycan, articular cartilage, aggregates structure and stability, *S2*/26, *S2*/29
—— —— —— aggregation in early experimental osteoarthrosis, *S2*/137
—— —— —— antisera, and hyaluronidase, effect on metabolic functions, calf *in vitro*, *S2*/59
—— —— —— charged group behaviour in relation to pH, *S2*/44
—— —— —— and collagen, breakdown organ culture, pig, 303
—— —— —— collagen interaction, impairment, in early experimental osteoarthrosis, 541, *P.*
—— —— —— discontinuous nature protein-keratan core, *S2*/42
—— —— —— and fibrils, interaction, *S2*/32
—— —— —— sulphated, release and degradation from cell layer of human chondrocytes, *S2*/75
—— —— —— synthesis, *S2*/52
Proteolytic enzymes, secretion, evidence of secretion from rheumatoid pannus and synovium, *S2*/71
Psoriasis, and HL-A antigens, family studies, *S1*/42
—— and spondylitis of chronic inflammatory disease, and HL-A W27, *S1*/31
Pulmonary stenosis, and cavernous haemangioma of lip, associated with pigmented villonodular synovitis in multiple joints: case report, 269
Pyrazole drugs, antinative DNA antibodies as a reaction to: case report, 373

RADIN, E. L., PAUL, I. L., and ROSE, R. M.: Mechanical factors in the aetiology of osteoarthrosis, *S2*/132
Radiological changes, 5–24 years, Azmoos, Switzerland, 199, *P.*
RAILTON, R., *see* ROONEY, P. J. *et al.*
RAJAN, K. T.: Observations on phagocytosis of urate crystals by polymorphonuclear leucocytes, 54
—— and MERKER, H. J.: Joint formation in culture, 200, *P.*
RATCLIFF, A. H., *see* VIDIGAL, E. *et al.*
RAU, R., PFENNINGER, K., and BONI, A.: Liver function tests and liver biopsies in patients with rheumatoid arthritis, 198, *P.*
REBUT-BONNETON, C., ROUCAYROL, J. C., and DELBARRE, F.: Effect of intra-articular injection of radioactive colloids of erbium and yttrium on the growth of rabbit legs, 529
REDLER, I.: Scanning electron microscope study of normal human articular cartilage, *S2*/5
—— Scanning electron microscopy of human osteoarthrotic cartilage, *S2*/23
REGINATO, A. J., HOLLANDER, J. L., MARTINEZ, V., VALENZUELA, F., SCHIAPACHASSE, V., COVARRUBIAS, E., JACOBELLI, S., ARINOVICHE, R., SILCOX, D., and RUIZ, F.: Familial chondrocalcinosis in the Chiloe Islands, Chile, 260
Reiter's syndrome, cardiac lesions, 195, *P.*
—— —— complement activation, 468, *P.*
—— —— and HL-A 27, *S1*/27
—— —— and HL-A antigens, *S1*/42
—— —— in three boys, 364
RENNOLDS, P., *see* STURROCK, R. D. *et al.*
RESNICK, D., *see* SHAPIRO, R. F. *et al.*
REYNOLDS, J., *see* LOEWI, G. *et al.*
Rheumatic disease, antiglobulins in Nigerians, 142
—— —— chronic inflammatory, hyperbasophilic immunoblasts in circulating blood, 422
—— —— histocompatibility, symposium, London, September 1974, supplement No 1, February 1975
—— —— (HL-A) W27-positive, aberrant immunity, *S1*/46
—— —— immunoglobulin phagocytosis by granulocytes in, 146
—— —— less common, establishment of National Case Register: correspondence, 275
—— —— osteocyte death, *S2*/143
Rheumatoid arthritis, alclofenac compared with phenylbutazone, double blind trial, 186
—— —— with antigen-antibody complexes, MIF production of lymphocytes, 117
—— —— antibody-mediated leucocyte cytotoxicity to Chang human liver cells, 544, *P.*
—— —— associated with aortic valve incompetence and replacement, 312, 464, *P.*
—— —— association with empyema, 181
—— —— cell mediated immunity to synovial antigens in, 196, *P.*
—— —— chronic, foot involvement, 292, 195, *P.*
—— —— elbow, joint involvement, and synovectomy with excision of radial head, 403
—— —— failure to show mycoplasmas and cytopathogenic virus in, 369
—— —— gold salt therapy in, 196, *P.*
—— —— joint damage, lack of correlation of synovial histology, 7, 199, *P.*
—— —— and juvenile chronic arthritis, eosinophil-specific and granulocyte-specific antinuclear antibodies in, 350, 468, *P.*
—— —— juvenile, defective cellular immunity, 196, *P.*
—— —— —— rubella antibody levels, 354
—— —— —— *see also* Still's disease
—— —— laboratory diagnosis, 85 patients, 395
—— —— liver function tests and liver biopsies, 198, *P.*
—— —— lymphocyte reactivity, mixed lymphocyte culture, 231
—— —— macrophage-lymphocyte clustering, 38
—— —— osteoporosis in patients with, 342, *P.*
—— —— plasma copper and caeruloplasmin concentrations, 162
—— —— —— zinc, relationship to corticosteroid therapy and osteoporosis, 201, *P.*
—— —— proteinase inhibitors, 225
—— —— raised plasma kininogen levels, response to indomethacin and relationship to clinical indices, 464, *P.*
—— —— relationship between antinuclear antibodies, DNA binding capacity and electroprecipitation, serum complement level, and the presence of soluble complexes in, 469, *P.*
—— —— rural South African Negro population, 136
—— —— and Sjøgren's syndrome, liver disease in, 70
—— —— in South African negro, 463, *P.*
—— —— synthetic D-penicillamine in, double-blind controlled study of high and low dosage regimen, 416
—— —— urban South African Negro population, 128
—— —— urinary copper excretion in, 340
—— —— virus antibodies in serum and synovial fluid, 43
—— cells, in culture, relationships, 235
Rheumatoid factors, family studies indicating genetic factors, *S1*/24
—— —— interpreting the biological significance, 463, *P.*
—— joints, *see* Joints
—— plantar synovial cysts: case report, 98
—— synovial membranes, *see* Synovial membranes
—— synovitis and joint disease, relationship between arthroscopic and histological changes, 1, 464, *P.*
Rheumatology, International Meeting, Israel, April 25–27, 1976, announcement, 545
—— and Mark Twain, 466, *P.*
RING, F. J., *see* POOLE, A. R. *et al.*
RNA antibodies, double-standard, in systemic lupus erythematosus, 239
ROBECCHI PRIZE, 1975, award winners, 544
ROBERTS, B. VERNON-, *see* VERNON-ROBERTS, B. *et al.*
ROBIN, G., *see* SOLOMON, L. *et al.*
ROBINSON, W. A., *see* GUPTA, R. *et al.*
ROOD, J. J. VAN, *see* VAN ROOD, J. J.
ROONEY, P. J., MCGAVIN, D. D. M., SUTHERLAND, G. R., and RAILTON, R.: Thin sclerae. A clinical illusion, 465, *P.*
ROPER, B. A., *see* BYERS, P. D. *et al.*
ROSE, R. M., *see* RADIN, E. L. *et al.*
ROSENBERG, J. N., JOHNSON, G. D., HOLBOROW, E. J., and BYWATERS, E. G. L.: Eosinophil-specific and other granulocyte-specific antinuclear antibodies in juvenile chronic polyarthritis and adult rheumatoid arthritis, 350, 468, *P.*

ROSIN, A. J.: Ectopic calcification around joints of paralysed limbs in hemiplegia, diffuse brain damage, and other neurological diseases, 499
ROUCAYROL, J. C., *see* REBUT-BONNETON, C. *et al.*
ROYAL MICROSCOPICAL SOCIETY International Symposia and exhibition (Micro '76), announcement, 544
Rubella antibody levels in juvenile rheumatoid arthritis, 354
—— in children with Still's disease, immunoglobulin levels, 204, *P.*
RUIZ, F., *see* REGINATO, A. J. *et al.*
RUTHERFORD, L., *see* AKESON, W. H. *et al.*

SAIRANEN, E., *see* AHO, K. *et al.*
SALMI, A., *see* KALLIOMÄKI, J. L. *et al.*
SCHIAPACHASSE, V., *see* REGINATO, A. J. *et al.*
SCHIFF, G. M., *see* LINNEMANN, C. C. *et al.*
SCHWARTZ, E.: Release and degradation of sulphated proteoglycans and collagen from the cell layer of human chondrocytes, *S2*/75
SCHWARTZ, E. R., GABRIEL, R., and THOMPSON, R. C.: Synthesis of cerebrosides in human articular cartilage, *S2*/62
Sclerae, thin, clinical illusion, 465, *P.*
SCOTT, J., *see* HOLIAN, J. *et al.*
SCOTT, J. E., CONOCHIE, L., FAULK, W. P., and BAILEY, A.: Passive agglutination method using collagen-coated tanned sheep erythrocytes to demonstrate collagen-glycosaminoglycan interaction, *S2*/38
—— and NEWTON, D.: Circadian rhythms in the excretion of urinary acid glycosaminoglycans, *S2*/63
SCOTT, J. T., *see* BREWIS, I. *et al.*
BUNN, D. N. *et al.*
FLETCHER, M. R., and SCOTT, J. T.
FLETCHER, M. R. *et al.*
YATES, D. B., and SCOTT, J. T.
YATES, D. B. *et al.*
SCUDDER, P., *see* MCMURRAY, W. *et al.*
SEEDHOM, B. B.: Load bearing function of the menisci of the knee joint, *S2*/118
SERAFINI-FRACASSINI, A., *see* WELLS, P., and SERAFINI-FRACASSINI, A.
SHAH, J. S., JAYSON, M. I. V., and HAMPSON, W. G.: A preliminary investigation of stress distribution in lumbar vertebrae, 199, *P.*
SHAPIRO, R. F., RESNICK, D., CASTLES, J. J., D'AMBROSIA, R., LIPSCOMB, P. R., and NIWAYAMA, G.: Fistulization of rheumatoid joints. A spectrum of identifiable syndrome, 489
SHARMA, J. N., ZEITLIN, I. J., BROOKS, P. M., and DICK, W. C.: Raised plasma kininogen levels in rheumatoid arthritis. Response to indomethacin and relationship to clinical indices, 464, *P.*
SI units, adoption in *Annals of the Rheumatic Diseases*, 259
SIDLER, J., *see* ANSELL, B. *et al.*
SIEGEL, N. J., *see* ADLER, M. K. *et al.*
SIEVERS, K., *see* AHO, K., *et al.*
SILCOX, D., *see* REGINATO, A. J. *et al.*
SILVERMAN, S., CONSTINE, L., HARVEY, W., and GRAHAME, R.: Survey of joint mobility and *in vivo* skin elasticity in London schoolchildren, 177
SIMON, W. H.: Wear properties of articular cartilage, *S2*/117
SINNIAH, R., *see* YEO, P. P. B., and SINNIAH, R.
SITKO, C., *see* EIBL, M. M., and SITKO, C.
Sjøgren's syndrome and rheumatoid arthritis, liver disease in, 70
Skin elasticity and joint mobility, survey in London schoolchildren, 177
SLATER, R. E., *see* NIKBIN, B. *et al.*
SLOPER, J. C., *see* YATES, D. B. *et al.*
SMITH, D. A., *see* KENNEDY, A. C. *et al.*
SMITH, T. W. D., BERGENHOLTZ, A., and LEMPERG, R.: Response of articular cartilage in organ growth hormone, *S2*/74
SNAITH, M. L., *see* BUNN, D. N. *et al.*
SOLOMON, L., BEIGHTON, P., VALKENBURG, H. A., and ROBIN, G.: Rheumatoid arthritis in the South African negro, 463
—— ROBIN, G., and VALKENBURG, H. A.: Rheumatoid arthritis in an urban South African negro population, 128
—— *see also* BEIGHTON, P. *et al.*
SORGENTE, N., *see* EISENSTEIN, R. *et al.*
KUETTNER, K. E. *et al.*
South African Rheumatism and Arthritis Association, biennial congress, Cape Town, May 10–14 1976, announcement, 378
SOWA, J. M., *see* LOVE, R. R., and SOWA, J. M.
Spine, lower mobility, end-plate defects, and disc degeneration, 201, *P.*
Spironolactone, and potassium metabolism in rheumatoid arthritis, 506
Staining in articular cartilage, alcian blue, *S2*/17
STANHOPE, J. M., and PRIOR, I. A. M.: Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers, 359
STEIN, H., DICKSON, R. A., and BENTLEY, G.: Rheumatoid arthritis of the elbow. Pattern of joint involvement, and results of synovectomy with excision of the radial head, 403
STEPHAN, R., *see* KLEINE, T. O., and STEPHAN, R.
STEPHENS, R., *see* GHOSH, P. *et al.*
STEVEN, F. S.: Interaction of cartilage collagen fibrils and proteoglycans, *S2*/32
STEVENS, R., *see* PHELPS, C., and STEVENS, R.
STEVENSON, R. D.: Stimulation of polymorph migration by a factor produced by steroid-treated monocytes, 202, *P.*
Stiffness, knee joint, quantitative study, 286
Still's disease, immunoglobulin levels during rubella in children with, 204, *P.*
—— —— *see also* Polyarthritis, juvenile chronic
STOCKS, J., *see* MCMURRAY, W. *et al.*
STOCKWELL, R. A.: Stain distribution with alcian blue in articular cartilage, *S2*/17
STOJAN, B.: A simple immunofluorescence method for differentiation of ANF between RA and healthy persons and SLE and scleroderma patients, 197, *P.*
Stress distribution, in lumbar vertebrae, 199, *P.*
STURROCK, R. D., BARRET, A. J., VERSEY, J., and RENNOLDS, P.: Raised levels of complement inactivation products in ankylosing spondylitis, 202, *P.*
—— DICK, H. M., HENDERSON, N., and DICK, W. C.: Family studies in ankylosing spondylitis, *S1*/39

—— FROEBEL, K., MACSWEEN, R. N. M., and DICK, W. C.: Evidence of impaired cell mediated immunity in the sero-negative arthritides, 203, *P.*
—— *see also* BROOKS, P. M. *et al.*
ROONEY, P. J. *et al.*
SUCH, C. H., UNSWORTH, A., WRIGHT, V., and DOWSON, D.: Quantitative study of stiffness in the knee joint, 286
SUTHERLAND, G. R., *see* ROONEY, P. J. *et al.*
SWANN, D. A.: Purification and properties of articular lubricant, *S2*/91
—— CAULFIELD, J. B., and CESELSKI, A.: Proteins associated with hyaluronic acid, *S2*/98
SWANSON, S. A. V., FREEMAN, M. A. R., and DAY, W. H.: Contact pressures in the loaded cadaver human hip, *S2*/114
SWINSON, D. R., HAMILTON, E. B. D., and DISCHE, F. E.: Penicillamine nephropathy, 544, *P.*
Synovectomy with excision of radial head in rheumatoid arthritis of the elbow, 403
Synovial antigens, cell mediated immunity to in rheumatoid arthritis, 196, *P.*
—— fluid in rheumatic disease, naturally-occurring anti-inflammatory factors, possible mode of action, 213
—— —— and serum, virus antibodies in rheumatoid arthritis and connective diseases, 43
—— histology, lack of correlations with joint damage in rheumatoid arthritis, 7, 199, *P.*
—— lining cells, and fibroblasts, proliferation, 219
—— membranes, inflamed, lymphoid cells from, 524
—— —— rheumatoid, DNA polymerase activity, 205
—— microcirculation, effects of prostaglandins, 540, *P.*
Synoviorthesis, behaviour of synovial complement C3 and C4 components in joint diseases before and after, 166, 197, *P.*
Synovitis, monoarticular, chronic, diagnostic and prognostic features, 171
—— pigmented villonodular, in multiple joints, child with cavernous haemangioma of lip and pulmonary stenosis: case report, 269
—— rheumatoid, and joint disease, relationship between arthroscopic and histological changes, 1, 464, *P.*

TAYLOR, T. K. F., *see* GHOSH, P. *et al.*
Temporo-mandibular joint disease in ankylosing spondylitis, 87, 468, *P.*
TERASAKI, P. *see* BLUESTONE, R. *et al.*
Tetracosactrin, and potassium metabolism in rheumatoid arthritis, 506
THADANI, U., *see* IVESON, J. M. I. *et al.*
THOMPSON, M., *see* DIXON, A. St. J. *et al.*
THOMPSON, R. C.: Experimental evidence for an injury threshold for articular cartilage, *S2*/140
—— *see also* SCHWARTZ, E. R. *et al.*
TIILIKAINEN, A., *see* AHO, K. *et al.*
TORZILLI, P. A., *see* MOW, V. C., and TORZILLI, P. A.
TRIBE, C. R., *see* HENDERSON, D. R. F. *et al.*
Tubercle aggregate size, influence of severity of adjuvant arthritis, rat, 49
TURNER, M. W., *see* OKAFOR, G. O. *et al.*

UNSWORTH, A., DOWSON, D., and WRIGHT, V.: Some new evidence on human joint lubrication, 277
—— *see also* DOWSON, D. *et al.*
SUCH, C. H. *et al.*
Urate crystals, phagocytosis, by polymorphonuclear leucocytes, 54
Uric acid, joint morbidity, and streptococcal antibodies in Maori and European teenagers, Rotorua lakes study 3, 359
—— —— serum level, relation to lean body mass, sex, plasma urea, intracellular potassium and packed cell volume in normal population group, 543, *P.*
Uveitis, acute anterior, and HL-A 27, *S1*/33

VALENZUELA, F., *see* REGINATO, A. J. *et al.*
VALKENBURG, H. A., *see* BEIGHTON, P. *et al.*
HALIM, W. *et al.*
SOLOMON, L. *et al.*
Valvular disease in chronic inflammatory disorders of connective tissue, factors influencing survival after surgery, 321
—— incompetence and replacement, in rheumatoid arthritis, 312
VAN DER KORST, J. K., *see* HALIM, W. *et al.*
VAN DER LINDEN, J. M. J. P., CATS, A., KEUNING, J. J., VAN ROOD, J. J., WUISMAN, J. H. C. HL-A 27 and ankylosing spondylitis, *S1*/53
VAN ELTEREN, PH., *see* HALIM, W. *et al.*
VAN HOOFF, J. P., *see* VAN ROOD, J. J. *et al.*
VAN ROOD, J. J., VAN HOOFF, J. P., and KEUNING, J. J.: Disease predisposition, immune responsiveness, and the fine structure of the HL-A supergene, *S1*/17
—— *see also* VAN DER LINDEN, J. M. J. P. *et al.*
Vascularization of cartilage, *S2*/76
VELVART, M., *see* FEHR, K. *et al.*
VERNON-ROBERTS, B., *see* CLARKE, A. K. *et al.*
LIYANAGE, S. P. *et al.*
VERSEY, J., *see* STURROCK, R. D. *et al.*
Vertebrae, lumbar, stress distribution, 199, *P.*
VIDIGAL, E., JACOBY, R. K., DIXON, A. ST. J., RATLIFF, A. H., and KIRKUP, J.: The foot in chronic rheumatoid arthritis, 292, 195, *P.*
VIGNON, E., ARLOT, M., MEUNIER, P., and VIGNON, G.: Histological changes in osteoarthritic femoral head cartilage, *S2*/134
—— *see also* VIGNON, E. *et al.*
Virus antibodies, serum and synovial fluid, rheumatoid arthritis and connective diseases, 43
—— cytopathogenic, and mycoplasmas, failure to show in rheumatoid arthritis, 369

WALKER, J. J., *see* BROOKS, P. M. *et al.*
WALKER, S., PRICE EVANS, D. A., BENN, P. A., LITTLER, T. R., and HALLIDAY, L. D. C.: Phenylbutazone and chromosomal damage, 409
WALSHE, J. M., *see* GOLDING, D. N., and WALSHE, J. M.
WARREN, R. E., *see* NIKBIN, B. *et al.*
WATSON, J., *see* BYWATERS, E. G. L., and WATSON, J.

WATSON, M. R., *see* BUNN, D. N. *et al.*
WEBB, F. W. S., BAKER, M., WEISBART, R., BLUESTONE, R., and GOLDBERG, L.: Macrophage-lymphocyte clustering in rheumatoid arthritis, 38
WEBB, J., WHALEY, K., MACSWEEN, R. N. M., NUKI, G., DICK, W. C., and BUCHANAN, W. W.: Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction, 70
WEBER, J. C. P., *see* DIXON, A. St. J. *et al.*
Weeping lubrication, approximate equation, solved with an electrical analogue, *S2*/85
WEIGHTMAN, B.: *In vitro* fatigue testing of articular cartilage, *S2*/108
—— *see also* KEMPSON, G. E. *et al.*
WEISBART, R., *see* WEBB, F. W. S. *et al.*
WEISBART, R. H., *see* BLUESTONE, R. *et al.*
WELLAND, H., *see* POOLE, A. R. *et al.*
WELLS, P. J., and SERAFINI-FRACASSINI, A.: Discontinuous nature of the protein-keratan sulphate core of cartilage proteoglycan, *S2*/42
WHALEY, K., *see* WEBB, J. *et al.*
WHITE, A. G., *see* MCMURRAY, W. *et al.*
WILCOX, W. R., and KHALAF, A. A.: Nucleation of monosodium urate crystals, 332
WILLOUGHBY, D. A.: Human arthritis applied to animal models: towards a better therapy: Heberden Oration, 1974, 471
Wilson's disease, musculoskeletal features, clinical, radiological and serological survey, 201, *P.*
WINSTOCK, D., *see* DAVIDSON, C. *et al.*
WINTERBURN, P. J., and PHELPS, C. F.: The actions of some anti-inflammatory and antirheumatic drugs on hexosamine biosynthesis, 200, *P.*
WIZE, J., ABGAROWICZ, T., WOJTECKA-LUKASIK, E., KSIEZNY, S., and DANCEWICZ, A. M.: Activation of human leucocyte procollagenase by rheumatoid synovial tissue culture medium, 520
WOJTECKA-LUKASIK, E., *see* WIZE, J. *et al.*
WOJTULEWSKI, J. A., *see* DAVIDSON, C. *et al.*
WOO, S. L-Y, *see* AKESON, W. H. *et al.*
WOOD, P. N. H., *see* BADLEY, E. M. *et al.*
BENN, T., and WOOD, P. H. N.
DICK, W. C. *et al.*
WOODROW, J. C.: Family studies (HL-A antigens), *S1*/42
WOOLLEY, D. E., LINDBERG, K. A., GLANVILLE, R. W., and EVANSON, J. M.: Action of rheumatoid synovial collagenase on cartilage collagen, *S2*/71
WRIGHT, V.: Family studies indicating genetic factors in rheumatic diseases, *S1*/24
WRIGHT, V., *see also* CHAMBERLAIN, M. A., and WRIGHT, V.
DICK, W. C. *et al.*
DOWSON, D. *et al.*
GVOZDANOVIC, D. *et al.*
IVESON, J. M. I. *et al.*
JOHNSON, G. R. *et al.*
JUTTLA, G., and WRIGHT, V.
MOLL, J. M. H. *et al.*
SUCH, C. H. *et al.*
UNSWORTH, A. *et al.*
Wrist, rheumatoid, cysts and fistulae, 388
WUISMAN, J. H. C., *see* VAN DER LINDEN, J. M. J. P. *et al.*
WUNSCH, M., *see* KLEINE, T. O., and WUNSCH, M.

Xeroradiographic techniques applied to assessment of Achilles tendon in inflammatory or metabolic diseases, 479

YATES, D. B., MAINI, R. N., SCOTT, J. T., and SLOPER, J. C.: Complement activation in Reiter's syndrome, 468, *P.*
—— and SCOTT, J. T.: Rheumatoid synovitis and joint disease. Relationship between arthroscopic and histological changes, 1, 464, *P.*
—— —— Cardiac valvular disease in chronic inflammatory disorders of connective tissue. Factors influencing survival after surgery, 321
YEO, P. P. B., and SINNIAH, R.: Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies, 457
Yttrium 90, colloidal, in knee joint tissues, histological studies, rabbits, 64
—— —— injection, followed by acute knee joint rupture, 62
—— and erbium, radioactive colloids, effect of intra-articular injection on growth of rabbit legs, 529

ZEITLIN, I. J., *see* GRENNAN, D. M. *et al.*
SHARMA, J. N. *et al.*
Zinc, plasma levels in rheumatoid arthritis, relationship to corticosteroid therapy and osteoporosis, 201, *P.*
ZINN, W. M., *see* ANSELL, B. *et al.*
ZUTSHI, D. W., *see* DIXON, A. St. J. *et al.*
ZYLINSKI, P., *see* HALL, M. A. *et al.*